

## CURRICULUM VITAE

**Name and Address:** SAMUEL WAXMAN, M.D.  
Division of Hematology/Oncology  
The Mount Sinai Medical Center  
One, Gustave L. Levy Place  
New York, NY 10029-6574

### **Current Academic and Professional Positions:**

2007 Distinguished Service Professor, Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine

2004-2007 Albert A. and Vera G. List Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine

1998 Co-Director, Joint Clinical Center for Cancer Therapy, Rui-Jin Hospital, Shanghai Second Medical University

1996 Honorary Professorship, Shanghai Second Medical University, Shanghai, China

1994-2004 Zena and Michael A. Wiener Professor of Medicine (Cancer), Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine

1992 Consultant Professor, Shanghai Second Medical University, Shanghai, China

1972 Head, Rochelle Belfer Chemotherapy Foundation Laboratory, Division of Medical Oncology, Mount Sinai Medical Center, New York, NY 10029

1983-1994 Clinical Professor of Medicine; Department of Medicine; Mount Sinai School of Medicine, New York, NY 10029

1983 Attending in Medicine; Department of Medicine; Mount Sinai Medical Center, New York, NY 10029

1976 Scientific Director, Samuel Waxman Cancer Research Foundation, 1150 Fifth Avenue, New York, NY 10128

### **Honors/Awards:**

1997 Magnolia Award, Shanghai Municipal Government, Shanghai, China  
1998 New York Magazine Hall of fame of New York physicians

### **Educational Background:**

B.S.	Cornell University, Ithaca, N.Y.	1953-1957
M.D.	State University of New York, Downstate Medical Center, Brooklyn, N.Y. (Summa Cum Laude)	1959-1963

### **Residency and Research Fellowships:**

Intern	The Mount Sinai Hospital, New York, NY	1963-1964
--------	--	-----------

Assistant Medical Resident	The Mount Sinai Hospital, New York, NY	1964-1965
Medical Resident	The Mount Sinai Hospital, New York, NY	1965-1966
Research Fellow in Hematology	The Mount Sinai Hospital, New York, NY	1966-1967
Research Fellow and Chief Resident	The Mount Sinai Hospital, New York, NY	1967-1968

**Academic and Professional Experience (1967-1983):**

Assistant Instructor in Medicine	Department of Medicine; Mount Sinai School of Medicine, New York, NY	1966- 1967
Instructor in Medicine	Department of Medicine; Mount Sinai School of Medicine, New York, NY	1967- 1968
Associate in Medicine	Department of Medicine, Mount Sinai School of Medicine, New York, NY	1969- 1970
Assistant Clinical Professor	Department of Medicine, Mount Sinai School of Medicine, New York, NY	1970- 1974
Associate Clinical Professor of Medicine	Department of Medicine, Mount Sinai School of Medicine, New York, NY	1974- 1983
Assistant Attending Physician	The Mount Sinai Hospital New York, NY	1970- 1974
Associate Attending Physician	The Mount Sinai Hospital New York, NY	1974- 1983
Attending Physician (Hematology)	Veteran's Hospital Bronx, NY	1970

**Board Certifications:**

Internal Medicine, 1970                      Subspecialty Boards in Hematology, 1972

**Professional Society and Organizational Membership:**

Member, Alpha Omega Alpha (1962-)  
Member, American Federation for Clinical Research (1969-)  
Member, American Society for Clinical Nutrition (1970-)  
Member, Subcommittee on Neoplasia, American Society of Hematology (1997-2001)  
Member, American Society of Hematology (1972-)  
Fellow, American College of Physicians (1972)  
Member, American Association for Cancer Research (1973-)  
Member, American Society for Clinical Investigation (1974-)  
Trustee, Leukemia Society of America, Inc. (1975-)  
Member, Medical Advisory Board, Leukemia Society of America, Inc. (1975-)  
Member, Harvey Society (1975-)  
Medical Director, Samuel Waxman Cancer Research Foundation (1976-)  
Member, Subcommittee on Nutritional Anemias, American Society of Hematology (1976-1980)  
Member, The International Society for Preventive Oncology (1977-)  
Member, Subcommittee on Neoplasia, American Society of Hematology (1982-1996)

Member, Subcommittee on Nutritional Education, American Society of Clinical Nutrition (1983-1986)  
Co-Organizer, International Conferences on Differentiation Therapy (1986-)  
Board of Directors, International Society of Differentiation (1988-)  
Editor, Differentiation (1991-)  
Editor, Molecular and Cellular Differentiation (1993-)  
Member, International Affairs Committee of American Association for Cancer Research (1995-)  
Associate Editor, Biological Regulators and Homeostatic Agents (1995-)  
Editorial Advisory Panel, Expert Review of Anticancer Therapy (2000-)  
Associate Editor, Cancer Research (2002-)

## **BIBLIOGRAPHY**

### **Reviewed Publications:**

1. Zucker MD, Hellman L, Zumoff B: Rapid disappearance of C14- labeled serotonin from platelets in patients with carcinoid syndrome. Research done as medical student. J. Lab. Clin. Med. 63: 137-146, 1964.
2. Cohen S, Waxman S: Myasthenia gravis, chronic lymphocytic leukemia and autoimmune hemolytic anemia - A spectrum of thymic abnormalities? Arch. Int. Med. 120: 717-720, 1967.
3. Metz J, Kelly A, Swett VC, Waxman S, Herbert V: Deranged DNA synthesis by bone marrow from Vitamin B12 deficient humans. Brit. J. Haematol. 14: 575-592, 1968.
4. Waxman S, Pratt P, Herbert V: Malabsorption of hemoglobin iron in pernicious anemia: Correction with intrinsic factor-containing substances. J. Clin. Invest. 57: 1819-1825, 1968.
5. Nossel HL, Niemetz J, Waxman S, Spector S: Defibrination Syndrome in a patient with chronic thrombocytopenic purpura. Amer. J. Med. 46: 591-598, 1969.
6. Waxman S, Metz J, Herbert V: Defective DNA synthesis in human megaloblastic marrow: The effect of homocysteine and methionine. J. Clin. Invest. 48: 284-289, 1968.
7. Waxman S, Herbert V: Mechanism of pyrimethamine-induced megaloblastosis in human bone marrow. New Eng. J. Med. 280: 1316-1319, 1969.
8. Waxman S, Dove JT: Cryofibrinogenemia aggravated during hypothermia. New Eng. J. Med. 281: 1291-1292, 1969.
9. Waxman S, Corcino J, Herbert V: Aggravation or initiation of megaloblastosis by amino acids available in the diet. J. Amer. Med. Assoc. 214: 101-104, 1970.
10. Corcino J, Waxman S, Herbert V: The mechanism of triamterene- induced megaloblastosis. Ann. Int. Med. 73: 419-424, 1970.
11. Waxman S, Corcino J, Herbert V: Drugs, toxins, and amino acids affecting B12 and folic acid absorption or utilization. Amer. J. Med. 48: 599-608, 1970.
12. Corcino J, Waxman S, Herbert V: Absorption and malabsorption of Vitamin B12. Amer. J. Med. 48: 562-569, 1970.
13. Corcino J, Krauss S, Waxman S, Herbert V: Release of Vitamin B12 binding protein by human leukocytes in vitro. J. Clin. Invest. 49: 2250-2255, 1970.
14. Corcino J, Waxman S, Herbert V: Uptake of tritiated folates by human bone marrow cells in vitro. Brit. J. Haematol. 20: 503-509, 1971.
15. Waxman S, Schreiber C, Herbert V: Radioisotope assay for measurement of serum folic acid. Blood 38: 219-228, 1971.
16. Waxman S, Schreiber C: Characteristics of folic acid binding protein in folate deficient serum. Blood 42: 291-301, 1973.

17. Waxman S, Schreiber C: Measurement of serum folate levels and serum folic acid binding protein by <sup>3</sup>H-PGA radioassay. *Blood* 42: 281- 290, 1973.
18. Waxman S: Metabolic approach to the diagnosis of megaloblastic anemias. *Med. Clin. N. America* 57: 315-334, 1973.
19. Price PM, Hirschhorn K, Gabelman N, Waxman S: In situ hybridization of RD114-Virus RNA with human metaphase chromosomes. *Proc. Natl. Acad. Sci. USA* 70: 11-14, 1973.
20. Hirschhorn K, Price PM, Gabelman N, Waxman S: The evolutionary significance of the persistence of latent oncogenic information in vertebrates. *Lancet* 1: 1158-1159, 1973.
21. Waxman S, Gilbert HS: A tumor-related vitamin B12 binding protein in adolescent hepatoma. *New Eng. J. Med.* 289: 1053-1056, 1973.
22. Waxman S, Gilbert HS: Characteristics of a novel serum vitamin B12 binding protein associated with hepatocellular carcinoma. *Brit. J. Haematol.* 27: 229-239, 1974.
23. Schreiber C, Waxman S: Measurement of red cell folate levels by <sup>3</sup>H-pteroylglutamic acid (<sup>3</sup>H-PteGlu) radioassay. *Brit. J. Haematol.* 27:551-558, 1974.
24. Waxman S, Schreiber C: The role of folic acid binding protein(s) in the cellular uptake of folates. *Proc. Soc. Exp. Biol. Med.* 147: 760- 764, 1974.
25. Waxman S: Annotation, Folate binding proteins. *Brit. J. Haematol.* 29: 23-29, 1975.
26. Waxman S, Schreiber C: Comments on folate radioassay. *Blood* 43: 313, 1974.
27. Bruckner HW, Schreiber C, Waxman S: The interaction of chemotherapeutic agents with methotrexate and 5-fluorouracil and its effect on de novo DNA synthesis. *Cancer Res.* 35: 801-806, 1975.
28. Greenberg ML, Waxman S: Sequential use of methotrexate, folinic acid and cytosine arabinoside in the treatment of acute leukemia. *Eur. J. Cancer* 12: 617-623, 1976.
29. Gabelman N, Waxman S, Smith W, Douglas SD: Spontaneous appearance of C-type particles in a human tumor cell line after co cultivation with rat (XC) cells. *Internatl. J. Cancer* 16: 355-369, 1975.
30. Burger RL, Waxman S, Gilbert HS, Mehlman CS, Allen RH: Isolation and characterization of a novel vitamin B12 binding protein associated with hepatocellular carcinoma. *J. Clin. Invest.* 56: 1262- 1270, 1975.
31. Waxman S, Schreiber C: The isolation of folate binding protein from commercially purified bovine beta lactoglobulin. *FEBS Lett.* 55: 128- 130, 1975.
32. Waxman S, Schreiber C: Purification and characterization of the low molecular weight human folate binding protein using affinity chromatography. *Biochemistry* 14: 5422-5428, 1975.
33. Levi RN, Waxman S: Schizophrenia, epilepsy, cancer, methionine and folate metabolism. A pathogenetic hypothesis for schizophrenia based upon their relationships. *Lancet* 2: 11-13, 1975.

34. Waxman S, Bruckner HW: Anti-tumor drug interactions - additional data. *Science* 194: 1112-1113, 1976.
35. Waxman S, Liu CK, Schreiber C, Helson L: The clinical and physiological implications of hepatoma B12 binding protein. *Cancer Res.* 37: 1908-1914, 1977.
36. Waxman S, Schreiber C: Varying effects of deoxynucleosides on the incorporation of thymidine into the DNA of monolayer and suspension cultures. *Proc. Soc. Exp. Biol. Med.* 154: 526-529, 1977.
37. Rubinoff M, Schreiber C, Waxman S: The isolation and characterization of folate binding protein from goat milk. *FEBS Lett.* 75: 244-248, 1977.
38. Liu CK, Schmied R, Greenspan EM, Waxman S: Characterization of sialyltransferase activity from human placenta. *Biochem. Biophys. Acta.* 522: 375-384, 1978.
39. Waxman S, Schreiber C, Rose M, Johnson I, Sheppard R, Sumbler K, Keen A, Guilford H: Measurement of serum folate by <sup>75</sup>Se- selenofolate radioassay: Results of a multi-institutional clinical trial. *Amer. J. Clin. Path.* 70: 27-31, 1978.
40. Zabos P, Kyner D, Mendelsohn N, Schreiber C, Waxman S, Acs G: Catabolism of 2-deoxyglucose by phagocytic leukocytes in the presence of 12-0-tetradecanoyl phorbol-13-acetate. *Proc. Natl. Acad. Sci. USA* 75: 5422-5426, 1978.
41. Liu CK, Schmied R, Waxman S: The specific release of sialyltransferase activity by human hepatoma cell lines. *Clin. Chim. Acta.*, 98: 225-233, 1979.
42. Waxman S, Liu CK, Schmied R: Abnormal glycoproteins and glycosyltransferases in human hepatoma. In: *Conf. on differentiation and carcinogenesis in liver cell cultures.* Ann. N.Y. Acad. Sci., 349: 411-412, 1980.
43. Bruckner HW, Rubinoff M, Waxman S: Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase. *Eur. J. Cancer* 16: 1057-1063, 1980.
44. Ohnuma T, Roboz J, Waxman S, Mandel E, Martin DS, Holland J: Clinical pharmacologic effects of thymidine plus 5-FU. *Cancer Treatment Reports* 64:1169-1177, 1980.
45. Liu CK, Schmied R, Waxman S: 12-0-tetradecanoyl-phorbol-13- acetate (TPA) release of glycosyltransferases from human blood cells. *J. Clin. Invest.* 65: 1365-1371, 1980.
46. Liu CK, Schmied R, Scher W, Waxman S: Alterations in glycosyltransferase levels in mouse erythroleukemia cells during erythrodifferentiation and cell growth. *Cancer Res.* 41: 790-794, 1981.
47. Rubinoff M, Abramson R, Schreiber S, Waxman S: Effects of a folate-binding protein on the plasma transport and tissue distribution of folic acid. *Acta Haematol.* 65: 145-152, 1981.
48. Grossowicz N, Waxman S, Schreiber C: Cryoprotected *Lactobacillus casei*: An approach to standardization of microbiological assay of folic acid in serum. *Clin. Chem.* 27: 745-747, 1981.
49. Liu CK, Schmied R, Waxman S: Characterization of galactosyltransferase released from human hepatoma cells. *Enzyme* 28: 258- 267, 1982.

50. Scher BM, Scher W, Robinson A, Waxman S: DNA ligase and DNAase I activities in mouse erythroleukemia cells during dimethyl sulfoxide-induced differentiation. *Cancer Res.* 42: 1300-1306, 1982.
51. Waxman S, Schreiber C, Waxman S: Evaluation of X-methyl folate preparations as possible folic acid antagonists. *Chemotherapy* 28: 402- 409, 1982.
52. Waxman S, Bruckner H: The enhancement of 5-fluorouracil, antimetabolic activity by leucovorin, menadione and a-tocopherol *Eur. J. Cancer*, 18: 685-692, 1982.
53. Scher W, Scher BM, Waxman S: Proteases stimulate mouse erythroleukemia cell differentiation and multiplication. *Biochem. Biophys. Res. Commun.* 109: 348-354, 1982.
54. Benesch R, Waxman S, Benesch R, Baugh C: The binding of folyl poly-glutamates by hemoglobin. *Biochem. Biophys. Res. Commun.* 106: 1359-1363, 1982.
55. Scher BM, Scher W, Waxman S: DNA ligase activity in extracts of mouse erythroleukemia (MEL) cells during differentiation. *Ann. N.Y. Acad. Sci.* 397: 315-316, 1982.
56. Liu CK, Schmied R, Schreiber C, Rosen C, Qian GX, Waxman S: Glycosyltransferase alterations are cell type related when human promyelocytic leukemia (HL-60) cells are treated with various inducers of differentiation. *Exp. Hematol.* 11: 738-746, 1983.
57. Scanlon KJ, Safirstein R, Thies H, Gross RB, Waxman S, Guttenplan JB: Inhibition of amino acid transport by cisplatin and its derivatives in L1210 murine leukemia cells. *Cancer Res.* 43: 4211- 4215, 1983.
58. Grossowicz N, Waxman S: Biotransformation of homofolate from a growth inhibitor to a growth promoting derivative. *Chemotherapy* 29: 6, 436-441, 1983.
59. Scher W, Scher BM, Waxman S: Proteases act synergistically with low molecular weight inducers to stimulate mouse erythroleukemia cell differentiation. *Exp. Hematol.* 11: 490-498, 1983.
60. Scanlon KJ, Berkowitz K, Pallai ME, Waxman S: Inhibition of methionine transport by methotrexate in mitogen stimulated human lymphocytes. *Cancer Treat. Rep.* 67: 631-639, 1983.
61. Scher BM, Scher W, Yeh HS, Waxman S: G-actin and F-actin levels at different stages of mouse erythroid differentiation. *Cell Biol. Internat. Rep.* 7: 661-667, 1983.
62. Scher W, Waxman S: Effects of dexamethasone and phorbol myristate acetate on the induction of differentiation in mouse erythroleukemic cells by dimethyl sulfoxide, proteases, and other compounds. *N.Y. Acad. Sci.* 411: 180-190, 1983.
63. Quian GX, Liu CK, Waxman S: Abnormal isoelectricfocusing patterns of serum galactosyltransferase in patients with liver neoplasia. *Proc. Soc. Exp. Biol. Med.* 175: 1-21, 1984.
64. Corrocher R, Abramson R, King VF, Schreiber C, Dikman S, Waxman S: Differential binding of folates by rat renal cortex brush border and baso-lateral membrane preparations. *Proc. Soc. Exp. Med. Biol.* 178: 73-84, 1985.
65. Scher BM, Scher W, Waxman S: Lack of evidence for activation of a serum factor in protease-induced differentiation of mouse erythroleukemia cells. *In Vitro Cell. Develop. Biol.* 21: 260-265, 1985.

66. Scher W, Hellinger N, Waxman S: Proteases induced hemoglobin synthesis, but not terminal cell division, in K562 cells. *Exp. Hematol.* 13:36-43, 1985.
67. Scher W, Scher B, Hellinger N, Waxman S: The proportions of hemoglobin types induced in mouse erythroleukemia cells vary with the inducer or combination of inducers, the inducer concentration and the time of induction. *Hemoglobin* 9: 577-596, 1985.
68. Waxman S, Scher W, Scher BM: Basic principles utilizing combination differentiation agents. *Cancer Det. and Preven.* 9: 395- 407, 1986.
69. Ghitis J, Waxman S: Modified phosphoribosylpyrophosphate (PRPP) radioenzymatic assay: increased sensitivity, technical simplification and new applications. *Clin. Chim. Acta:* 164: 267-273, 1987.
70. Ghitis J, Schreiber C, Waxman S: Phosphate induced phosphoribosylpyrophosphate (PRPP) elevations to assess deranged folate and purine nucleotide metabolism. *Proc. Soc. Exp. Biol. Med.* 186: 90- 95. 1987.
71. Kane MA, Roth E, Raptis G, Schreiber C, Waxman S: The effect of intracellular folate concentration on the modulation of 5- fluorouracil cytotoxicity by the elevation of phosphoribosyl pyrophosphate in cultured human KB cells. *Cancer Res.* 47: 6444- 6450, 1987.
72. Slosberg EA, Scher BM, Scher W, Josephson S, Waxman S: Induction of differentiation in mouse erythroleukemia cells by the action of papain at the cell surface. *Cell and Tissue Kinetics* 20:571- 581, 1987.
73. Kane MA, Elwood PC, Portillo RM, Antony AC, Najfeld V, Finley A, Waxman S, Kolhouse FJ: Influence on immunoreactive folate binding proteins of extracellular folate concentration in cultured human cells. *J. Clin. Invest.* 81:1398-1406, 1988.
74. Scher BM, Scher W, Waxman S: A possible effect of heme on the fate of DNA ligase activity extracted from differentiating mouse erythroleukemia cells. *Cancer Res.* 48:6278-6284, 1988.
75. Waxman S: The importance of the induction of gene expression and differentiation by cytotoxic chemotherapy. *Cancer Investigation* 6:747-753, 1988.
76. Scher W, Scher BM, Hellinger N, Waxman S: Benzyl Alcohol (BA) reduces the accumulation of hemoglobin minor (Hb mn) compared to hemoglobin major (Hb mj) in mouse erythroleukemia (MEL) cells induced to differentiate by dimethyl sulfoxide (DMSO) and hexamethylene bisacetamide (HMBA). *Ann. N.Y. Acad. Sci.* 567:314-317, 1989.
77. Scher BM, Scher W, Waxman S: Studies on the DNA ligase of mouse erythroleukemia (MEL) cells: Therapeutic Implications. *Ann. N.Y. Acad. Sci.* 567:347-348, 1989.
78. Kane M, Waxman S: Biology of Disease: The role of folate binding proteins in folate metabolism. *Lab. Invest.* 60:736-747, 1989.
79. Chou J-L, Shen Z-X, Stolfi RL, Martin DS, Waxman S: Effects of extracellular matrix on the growth and casein gene expression of primary mouse mammary tumor cells in vitro. *Cancer Res.* 49: 5371-5376, 1989.
80. Scher W, Scher BM, Hellinger N, Waxman S: Benzyl alcohol alters the hemoglobin phenotype of mouse erythroleukemia cells. *J. Biol. Regulators Homeostat. Agents.,* 3:91-97, 1989.



81. Shao G-Y, Liu C-K, Waxman S: Rapid alterations in protein kinase C activity and intracellular distribution during phorbol ester-induced HL-60 cell macrophage-like differentiation. *J. Shanghai Second Medical University* 86-94, 1989.
82. Chou J-L, Shen Z-X, Tan I-J, Stolfi RL, Martin DS, Dikman SH, Waxman S: In vitro and in vivo growth and casein gene expression of mouse mammary tumor epithelial cells in response to hormones. *Experimental Cell Res.* 186:250-256, 1990.
83. Waxman S, Scher BM, Hellinger N, Scher W: Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5- fluorouracil and hexamethylene bisacetamide. *Cancer Res.* 50:3878-3887, 1990.
84. Wu H, Scher BM, Chu CL, Leonard M, Olmedo R, Scher GS, Stecker S, Scher W, Waxman S: Reduction in lactate accumulation correlates with differentiation-induced terminal cell division of leukemia cells. *Differentiation* 48:51-58, 1991.
85. Jiang H, Su Z-Z, Datta S, Guarini L, Waxman S, Fisher PB: Fludarabine phosphate selectively inhibits growth and modifies the antigenic phenotype of human glioblastoma multiforme cells expressing a multidrug resistance phenotype. *International J. Oncology* 1:227-239, 1992.
86. Chen S-J, Chen Z, Chen A, Tong J-H, Dong S, Wang Z-Y, Waxman S, Zelent A: Occurrence of Distinct PML-RAR-aD Fusion Gene Isoforms in Patients with Acute Promyelocytic Leukemia detected by Reverse Transcriptase/Polymerase Chain Reaction. *Oncogene* 7:1223-1232, 1992.
87. Waxman S, Huang Y, Scher BM, Scher W: Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers; Development of DNA double-strand breaks. *Biomedicine and Pharmacotherapy* 46, 183:192, 1992.
88. Mira-y-Lopez R, Jaramillo S, Waxman S: Redundant regulation of urokinase plasminogen activator transcription by the two major isozymes of c-AMP dependent protein kinase. *J. Biol. Chem.* 267:23063-23068, 1992.
89. Leon JA, Gutierrez MC, Jiang H, Estabrook A, Waxman S, Fisher P: Modulation of antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons. *Cancer Immunol. and Immunother.* 35:315-324, 1992.
90. Chen Z, Brand NJ, Chen A, Chen S-J, Tong J-H, Wang Z-Y, Waxman S, Zelent A: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor - alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. *EMBO J.* 12: 1161-1167, 1993.
91. Chen S-J, Zelent A, Tong J-H, Wang Z-Y, Derre J, Berger R, Waxman S, Chen Z: Rearrangements of the retinoic acid receptor alpha and PLZF genes resulting from t(11;17) (q23;q21) in a patient with acute promyelocytic leukemia. *J. Clin. Invest.* 91:2260-2267, 1993.
92. Chang T-J, Scher BM, Waxman S, Scher W: Inhibition of mouse GATA-1 function by the glucocorticoid receptor: Possible mechanism of steroid inhibition of erythroleukemia cell differentiation. *Molecular Endocrinology* 7:528-542, 1993.
93. Borden E, Lotan R, Levens D, Young C, Waxman S: Differentiation Therapy of Cancer; Laboratory and Clinical Investigations. *Cancer Res.* 53:4109-4115, 1993.

94. Huang W, Sun G-L, Li X-S, Cao Q, Yu Y, Jang G-S, Zhang F-Q, Chai J-R, Wang Z-Y, Waxman S, Chen Z, Chen S-J: Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. *Blood* 82:1264-1269, 1993.
95. Lazega D, Schenker E, Busso N, Zelent A, Chen A, Waxman S: Down-regulation of retinoic acid receptor activity associated with decreased alpha and gamma isoforms expression in F9 embryonal carcinoma cells differentiated by retinoic acid. *J Cellular Physiol.* 157:90-96, 1993.
96. Jiang H, Waxman S, Fisher PB: Regulation of c-fos, c-jun and jun-B gene expression in human melanoma cells induced to terminal differentiation. *Molecular and Cellular Differentiation* 2:197-214, 1993.
97. Guidez F, Huang W, Tong J-H, Dubois C, Balitrand N, Waxman S, Michaux JL, Martizi P, Degos L, Chen Z, Chomienne C: Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. *Leukemia* 8:312-317, 1994.
98. Chen Z, Guidez F, Rousselot P, Agadir A, Chen S-J, Wang Z-Y, Degos L, Zelent A, Waxman S, Chomienne C: PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibits ligand-dependent transactivation of wild-type retinoic acid receptors. *Proc. Natl. Acad. Sci. USA* 91:1178-1182, 1994.
99. Huang Y, Waxman S: Enhanced apoptosis in leukemia cells following treatment with combination fluoropyrimidines and differentiation inducers. *Molecular and Cellular Differentiation.* 2:83-100, 1994.
100. Najfeld V, Chen A, Scalise A, Ambinder E, Fernandez G, Waxman S: Myelodysplastic syndrome transforming to acute promyelocytic-like leukemia with trisomy and rearrangement of chromosome 11. *Genes, Chromosomes and Cancer* 10:15-25, 1994.
101. Scott A, Head D, Kopecky K, Applebaum F, Thiel K, Grever M, Chen IM, Whittaker M, Griffith B, Licht J, Waxman S, Whalen M, Bankhurst A, Richter L, Grogan T, Willman C: HLA-DR<sup>-</sup>, CD33<sup>+</sup>, CD36<sup>+</sup>, CD56<sup>+</sup>, CD16 myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia - M3. *Blood* 84:224-255, 1994.
102. Busso N, Masur S, Lazega D, Waxman S, Ossowski L: Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. *J. Cell Biology* 126:259-270, 1994.
103. Chen A, Licht J, Wu Y, Hellinger N, Scher W, Waxman S: Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. *Blood* 84:2122-2129, 1994.
104. Chang T-J, Scher BM, Waxman S, Scher W: GATA-1 and the glucocorticoid receptor can influence transcriptional regulation of erythropoietic viral sequences: Friend leukemia virus and B19 parvovirus. *Mol. and Cell. Differentiation* 2:289-308, 1994.
105. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH, Zelenetz AD, Willman CL, Chen Z, Chen SJ, Macintyre E, Veil A, Cortes J, Kantarjian H, Waxman S: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17), *Blood* 85:1083-1094, 1995.

106. Zhu J, Shi X-G, Chu H-Y, Tong J-H, Wang Z-Y, Waxman S, Naoe T, Chen S-J, Chen Z: Retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell Line NB4. *Leukemia* 9:302-309, 1995.
107. Cook M, Gould A, Brand N, Davies J, Strun P, Shaknovich R, Licht J, Waxman S, Chen Z, Gluecksohn-Waelsch S, Krumlauf R, Zelent A: Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain. *Proc. Natl. Acad. Sci. USA* 92: 2249-2253, 1995.
108. Jing Y, Waxman S: Structural requirements for differentiation-induction and growth-inhibition of mouse erythroleukemia cells by isoflavones. *Anticancer Research* 15:1147-1152, 1995.
109. Huang Y, Scher BM, Waxman S: Combination cytotoxic-differentiation therapy-induced apoptosis correlates with decrease in intracellular pH and activation of an endonuclease. *Mol. and Cell. Differentiation* 3: 241-260, 1995.
110. Su Z-Z, Jiang H, Waxman S, Goldstein NI, Fisher PB: Reversible and terminal differentiation in human melanoma cells enhances fibronectin and integrin gene expression. *Mol. and Cell. Differentiation* 3: 225-239, 1995.
111. Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R, Zelent A: Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. *Blood* 86: 4544-4552, 1995.
112. Jiang H, Lin J, Young S-M, Goldstein N, Waxman S, Davila V, Chellappan SP, Fisher PB: Expression and E2F transcription factor complexes in human melanoma cells induced to terminally differentiate. *Oncogene* 11: 1179-1189, 1995.
113. Zhang S-Y, Zhu J, Chen G-Q, Du X-X, Lu L-J, Zhang Z, Zhong H-J, Chen H-R, Wang Z-Y, Berger R, Lanotte M, Waxman S, Chen Z, Chen S-J: Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice. *Blood* 87: 3404-3409, 1996.
114. Manfredi JJ, Tang H-Y, Waxman S: The Cyclin-dependent kinase inhibitor p21 as a target for differentiation therapy. *Mol. and Cell. Differentiation* 4: 33-45, 1996.
115. Licht JD, Shaknovich R, Melnick A, English MA, Li J-Y, Reddy JC, Dong S, Chen S-J, Zelent A, Waxman S: Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor- $\alpha$  Chimera generated in t(11;17)-associated acute promyelocytic leukemia. *Oncogene* 12: 323-336, 1996.
116. Dong S, Zhu J, Reid A, Strutt P, Guidez F, Zhong H-J, Wang Z-Y, Licht J, Waxman S, Chomienne C, Chen Z, Zelent A, Chen S-J: Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor- $\alpha$  fusion protein. *Proc Natl Acad Sci, USA* 93:3624-3629, 1996.
117. Mao M, Yu M, Tong J-H, Ye J, Zhu J, Huang Q-H, Yu L, Zhao S-Y, Waxman S, Lanotte M, Wang Z-Y, Tan J-Z (Tan CC), Chen S-J, Chen Z: RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. *Proc. Natl. Acad. Sci. USA* 93:5910-5914, 1996.
118. Jing Y, Zhang J, Bleiweiss IJ, Waxman S, Zelent A, Mira-y-Lopez R: Defective expression of cellular retinol binding protein type I and retinoic acid receptors  $\alpha$ 2,  $\beta$ 2 and  $\gamma$ 2 in human breast cancer cells. *FASEB J* 10:1064-1070, 1996.

119. Jing Y, Zhang J, Waxman S, Mira-y-Lopez R: Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. *Differentiation* 60:109-117, 1996.
120. Waxman S: Meeting report: Molecular biology of normal development, malignancy and its suppression. *Oncogene* 12: 2247-2250, 1996.
121. Jing Y, Xu X-C, Lotan R, Waxman S, Mira-y-Lopez R: Human breast carcinoma slice cultures retain retinoic acid sensitivity. *Brazilian Journal of Medical & Biological Res* 29: 1-4, 1996.
122. Jing Y, Waxman S, Mira-y-Lopez R: The cellular retinoic acid-binding protein II (CRABPII) is a positive of retinoic acid signaling in breast cancer cells. *Cancer Res* 57:1668-1672, 1997.
123. Chen G-Q, Shi X-G, Tang W, Xiong S-M, Zhu J, Cai X, Han Z-G, Ni J-H, Shi G-Y, Jia P-M, Liu M-M, He K-L, Niu C, Ma J, Zhang P, Zhang T-D, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang Z-Y, de The H, Chen S-J, Chen Z: Use of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in the treatment of acute promyelocytic leukemia (APL): I. As<sub>2</sub>O<sub>3</sub> exerts dose-dependent dual effects on APL cells. *Blood* 89: 3345-3353, 1997.
124. Yu M, Tong J-H, Mao M, Kan L-X, Liu M-M, Su, Y-W, Fu G, Jing Y-K, Yu L, Lepaslier D, Lanotte M, Wang Z-Y, Chen Z, Waxman S, Wang Y-X, Tan J-Z, Chen S-J: Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of the interferon-stimulated genes. *Proc. Natl. Acad. Sci. USA* 94: 7406-7411, 1997.
125. Koken MHM, Reid A, Quignon F, Chelbi-Alix MK, Davies JM, Kabarowski JHS, Zhu J, Dong S, Chen S-J, Chen Z, Tan CC, Licht J, Waxman S, de The H, Zelent A: Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. *Proc. Natl. Acad. Sci. USA* 94: 10255-10260, 1997.
126. Li J-Y, English MA, Ball HJ, Yeyati PL, Waxman S, Licht JD: Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. *J. Biol. Chem.* 272: 22447-22455, 1997.
127. Scher BM, Chen JY-H, Fuksina I, Waxman S, Scher W: Induction of erythroid differentiation is associated with inhibition of glycolysis and a decrease in fructose 2,6-bisphosphate levels. *Int. J. Oncol.* 11: 1135-1140, 1997.
128. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. *J. Natl. Cancer Inst.* 90: 124-133, 1998.
129. Guidez F, Ivins S, Zhu J, Söderström M, Waxman S, Zelent A: Reduced retinoic acid-sensitivities of nuclear receptor co-repressor binding to PML- and PLZF-RAR alpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. *Blood* 91: 2634-2642, 1998.
130. Scher BM, Fuksina I, Hellinger N, Waxman S, Scher W: The phosphatase inhibitors, orthovanadate and levamisole, inhibit induction of erythroid differentiation and abrogate the associated inhibition of glycolysis. *Int. J. Oncol.* 12: 987-996, 1998.

131. Shaknovich RS, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A, Licht JD: The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. *Molecular and Cellular Biology* 18: 5533-5545, 1998.
132. Thiele CJ, Waxman S, Chomienne C: Differentiation or death; the view from Versailles. *Cell Death and Differentiation* 5: 716-718, 1998.
133. Huang Y, Waxman S: Enhanced growth inhibition and differentiation of fluorodeoxyuridine treated human colon carcinoma cells by phenylbutyrate. *Clin. Cancer Res* 4: 2503-2509, 1998.
134. Dai J, Weinberg RS, Waxman S, Jing Y-K: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by As<sub>2</sub>O<sub>3</sub> through modulation of the glutathione redox system. *Blood* 93: 268-277, 1999.
135. Jing Y, Nakajo S, Xia L, Nakaya K, Fang Q, Waxman S, Han R: Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. *Leukemia Res.* 23: 43-50, 1999.
136. Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Nason-Burchenal K, Dmitrovsky E, Zelent A, Licht JD: Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. *Oncogene* 18: 925-934, 1999.
137. Zhu X-H, Dai J, Cai X, Shi X-G, Jia P-M, Jing Y-K, Xiao D-M, Xiong S-M, Tang W, Wang L, Pan L, Shi G-Y, Wang Z-Y, Chen Z, Zhang T-D, Waxman S, Chen S-J, Chen G-Q: Arsenic trioxide induces growth inhibition and apoptosis in malignant lymphocytic cells at clinically achievable concentrations. *J. Natl. Cancer Inst.* 91: 772-778, 1999.
138. Chen G-X, Zhu X-H, Men X-Q, Wang L, Huang Q-H, Jin XL, Xiong S-M, Zhu J, Guo W-M, Chen J-Q, Xu S-F, So E, Chan L-C, Waxman S, Zelent A, Chen G-Q, Dong S, Liu J-X, Chen S-J: Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RAR alpha and NPM-RAR alpha. *Proc. Natl. Acad. Sci. USA* 96:1-6, 1999.
139. van Schothorst EM, Prins DEM, Baysal BE, Beekman M, Licht JD, Waxman S, Zelent A, Cornelisse CJ, van Ommen GJB, Richard III CW, Devilee P: Genomic structure of the human PLZF gene. *Gene* 236:21-24, 1999.
140. Jing YK, Dai J, Chalmers-Redman RME, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. *Blood* 94: 2102-2111, 1999.
141. Waxman S, Jing YK, Chen Z, Chen G-Q: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations (Correspondence). *J. Natl. Cancer Inst.* 91: 1691, 1999.
142. Niu C, Hua Y, Liu J-X, Yu T, Sun H-P, Li X-S, Wu W, Zhang F-Q, Chen Y, Zhou L, Li J-M, Zeng X-Y, Yang R-R, Yuan M-M, Ren M-Y, Gu F-Y, Gu B-W, Cao Q, Su X-Y, Chen GQ, Xiong S-M, Zhang T-D, Waxman S, Wang Z-Y, Chen Z, Hu J, Shen Z-X, Chen S-J: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. *Blood* 94: 3315-3324, 1999.

143. Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Waxman S, Mira-y-Lopez R: Cellular retinol-binding protein expression and breast cancer. *J. Natl. Cancer Inst.* 92: 475-480, 2000.
144. Waxman S: Differentiation therapy in acute myelogenous leukemia (non-APL). *Leukemia* 14: 491-496, 2000.
145. Huang Y, Horvath CM, Waxman S: Regrowth of 5-fluorouracil treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin and phenylbutyrate. *Cancer Res.* 60: 3200-3206, 2000.
146. Liu T-X, Zhang J-W, Tao J, Zhang R-B, Zhang Q-H, Zhao C-J, Tong J-H, Lanotte M, Waxman S, Chen S-J, Mao M, Hu G-X, Zhu L, Chen Z: Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. *Blood* 96: 1496-1504, 2000.
147. Thiele CJ, Gore S, Collins S, Waxman S, Miller W: Differentiate or die: the view from Montreal. *Cell Death and Differentiation* 7: 1014-1017, 2000.
148. Jing Y, Wang L, Xia L, Chen G-Q, Chen Z, Miller WH, Waxman S: Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. *Blood* 97: 264-269, 2001.
149. Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S, Malavasi F: Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide on myeloma cells. *Leukemia Res.* 25: 227-235, 2001.
150. Waxman S, Anderson KC: History of the development of arsenic derivatives in cancer therapy. *The Oncologist* 6 (suppl 2): 3-10, 2001.
151. Zhu J, Heyworth CM, Huang H-Q, Petrie K, Lanotte M, Benoit G, Gallagher R, Waxman S, Enver T, Zelent A: Lineage restriction of the RAR alpha gene expression in myeloid differentiation. *Blood* 98: 2563-2567, 2001.
152. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD: Translocations of the RARa gene in acute promyelocytic leukemia. *Oncogene* 20: 7186-7203, 2001.
153. Zhu Q, Zhang J-W, Zhu H-Q, Shen Y-L, Flexor M, Jia P-M, Yu Y, Cai X, Waxman S, Lanotte M, Chen S-J, Tong J-H: Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. *Blood* 99: 1014-1022, 2002.
154. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD: Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. *The Oncologist* 7 (suppl 1): 1-13, 2002.
155. Miller, Jr. WH, Waxman S: Differentiation induction as a treatment for hematologic malignancies. *Oncogene* 21: 3496-3506, 2002.
156. Anderson KC, Boise LH, Louie R, Waxman S: Arsenic trioxide in multiple myeloma: rationale and future directions. *Cancer J* 8: 12-25, 2002.
157. Gu BW, Xiong H, Zhou Y, Chen B, Wang L, Dong S, Yu ZY, Lu LF, Zhong M, Ying HF, Zhu GF, Huang W, Ren SX, Gallagher RE, Waxman S, Chen GQ, Wang ZG, Chen Z, Fu G, Chen SJ: Variant-type PML-RARalpha fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding

sequence from intron 2 of the RARalpha gene and identification of a new clinical subtype resistant to retinoic acid therapy. *Proc. Natl. Acad. Sci. USA* 99: 7640-7645, 2002.

158. Miller Jr., WH, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of action of arsenic trioxide. *Cancer Res* 62: 3893-3903, 2002.
159. Jing Y, Xia L, Waxman S: Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. *Blood* 100: 1008-1013, 2002.
160. Farias EF, Arapshian A, Bleiweiss IJ, Waxman S, Zelent A, Mira-y-Lopez R: Retinoic acid receptor alpha2 is a growth suppressor epigenetically silenced in MCF-7 human breast cancer cells. *Cell Growth & Differentiation* 13: 335-341, 2002.
161. Lo Coco F, Zelent A, Kimchi A, Carducci M, Gore SD, Waxman S: Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond. *Cancer Res* 62: 5618-5621, 2002.
162. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. *Molecular Cancer Therapeutics* 1: 851-860, 2002.
163. Chen G-Q, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. *Cancer Res* 63: 1853-1859, 2003.
164. Petri K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, Zelent A. The histone deacetylase 9 gene encodes multiple protein isoforms. *J Biol Chem* 278: 16059-16072, 2003.
165. Mann KK, Raphaeli A, Colosimo AL, Diaz Z, Nudelman A, Levovich I, Jing Y, Waxman S, Miller WH Jr. A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. *Molecular Cancer Res* 1: 903-912, 2003.
166. Lebedeva IV, Su Z-Z, Sarkar D, Kitada S, Dent P, Waxman S, Reed JC, Fisher PB. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. *Cancer Res* 63: 8138-8144, 2003.
167. Zhao Q, Tao J, Zhu Q, Jia PM, Dou AX, Li X, Cheng F, Waxman S, Chen GQ, Chen SJ, Lanotte M, Chen Z, Tong JH. Rapid induction of cAMP/PKA pathway during retinoic acid induced acute promyelocytic leukemia cell differentiation. *Leukemia* 18, 285-292, 2004.
168. Davison K, Mann KK, Waxman S, Miller WH Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. *Blood* 103, 3496-3502, 2004.
169. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As<sub>2</sub>O<sub>3</sub> combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. *Proc. Natl. Acad. Sci. USA* 101: 5328-5335, 2004.
170. Davison K, Mann KK, Waxman S, Miller WH Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. *Blood* 103: 3496-3502, 2004.

171. Lu M, Xia L, Luo D, Waxman S, Jing Y. Dual effects of glutathione-S-transferase pi on As<sub>2</sub>O<sub>3</sub> action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. *Oncogene* 23: 3945-3952, 2004.
172. Zelent A, Waxman S, Carducci M, Wright J, Zweibel J, Gore SD. State of the translational science: Summary of Baltimore Workshop on gene re-expression as a therapeutic target in cancer January 2003. *Clinical Cancer Research* 10: 4622-4629, 2004.
173. Lebedeva IV, Su Z-z, Sarkar D, Gopalkrishnan R, Waxman S, Yacoub A, Dent P, Fisher PB. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. *Oncogene* 24: 585-596, 2005.
174. Zelent A, Petrie K, Chen Z, Lotan R, Lubbert M, Tallman MS, Ohno R, Degos L, Waxman S. Molecular target-based treatment of human cancer: summary of the 10<sup>th</sup> International Conference on Differentiation Therapy. *Cancer Research* 65: 1117-1123, 2005.
175. Xia L, Chen D, Han R, Fang Q, Waxman S, Jing Y. Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. *Mol Cancer Ther* 4: 381-388, 2005.
176. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, Cui J, Chen ZM, Cao Q, Yang G, Yao Y, Xia HL, Tong JH, Li JM, Chen J, Xiong SM, Shen ZX, Waxman S, Chen Z, Chen SJ. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. *Leukemia* 19: 767-775, 2005.
177. Zhou L, Jing Y, Styblo M, Chen Z, Waxman S. Glutathione-S-transferase pi inhibits As<sub>2</sub>O<sub>3</sub>-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. *Blood* 105: 1198 – 1203, 2005.
178. Zheng P-Z, Wang K-K, Zhang Q-Y, Huang Q-H, Du Y-Z, Zhang Q-H, Xiao D-K, Shen S-H, Imbeaud S, Eveno E, Zhao C-J, Chen Y-L, Fan H-Y, Waxman S, Auffray C, Jin G, Chen S-J, Chen Z, Zhang J. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. *Proc Natl Acad Sci USA* 102: 7653-7658, 2005.
179. JingY, Hellinger N, Xia L, Monks A, Sausville EA, Zelent A, Waxman S. Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. *Cancer Research* 65: 7847-7855, 2005.
180. Xu K, Guidez F, Glasow A, Chung D, Petrie K, Stegmaier K, Wang K-K, Zhang J, Jing Y, Zelent A, Waxman S. Benzodithiophenes potentiate differentiation of APL cells by lowering the threshold for ligand mediated co-repressor/coactivator exchange with RAR alpha and enhancing changes in ATRA regulated gene expression. *Cancer Research* 65: 7856-7865, 2005.
181. Zelent A, Petrie K, Lotan R, Waxman S, Gore SD. Clinical translation of epigenetics in cancer: eN-CORE—a report on the second work shop. *Mol Cancer Ther* 4: 1810-1819, 2005.
182. Xia L, Wurmbach E, Waxman S, Jing Y. Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. *Leukemia* 20: 1009-1016, 2006.
183. Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, Mandeli J, O'Connell MJ, Waxman S, Germain D. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. *J Natl Cancer Inst* 98: 1238-1247, 2006.



184. Chen D, Chan R, Waxman S, Jing Y. Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. *Cancer Research* 66: 11416-11423, 2006.
185. Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. *Cancer Research* 66: 11360-11369, 2006.
186. Llovet JM, Chen Y, Wurbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. *Gastroenterology* 131: 1758-1767, 2006.
187. Wurbach E, Chen Y, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. *Hepatology* 45: 938-947, 2007.
188. Lebedeva IV, Su Z-Z, Emdad L, Kolomeyer A, Sarkar D, Kitada S, Waxman S, Reed JC, Fisher PB. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. *Oncogene* 26: 733-744, 2007.
189. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. *Anticancer Agents Med Chem.* 3:359-65, 2007.
190. Sung MW, Waxman S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. *Anticancer Res.* 27:995-1001, 2007.

### **Books, Chapters and Review Articles:**

1. Waxman S: Molecular Biology of anti-cancer agents. In: Clinical Cancer Chemotherapy. EM Greenspan, Ed., Raven Press, New York, 1975, p. 17-31.
2. Waxman S: The role of folate binding proteins in folate metabolism. In: Chem. and Biol. of Pteridines. W Pfeleiderer, Ed., W. de Gruyter, Berlin; New York, p. 165-168, 1975.
3. Waxman S, Schreiber C: Measurement of serum folate levels: Current status of the methodology. In: Folic Acid, Biochemistry and Physiology in Relation to the Human Nutritional Requirement. Natl. Acad. Sci., Washington p. 98-109, 1977.
4. Waxman S: The value of measurement of folate levels by radioassay: In: Folic acid in neurology, psychiatry and internal medicine. MI Botex and EH Reynolds, Eds., Raven Press, New York, 1979, p. 47-55.
5. Waxman S, Schreiber C, Rubinoff M: The significance of folate binding proteins in folate metabolism: In: Advances in Nutritional Research, Vol. 1. Draper HD, Ed., Plenum Publishing Corp, New York, 1977, p. 55-76.
6. Waxman S: Studies on the origin of folate binding proteins. In: Chem. and Biol. of Pteridines. RL Kisliuk and GM Brown, Eds., Elsevier/N. Holland, New York, 1979, p. 619-624.
7. Waxman S: Prospectives for leukemia research and therapy. In: The Leukemia Cell., Rubin A and Waxman S, Eds., CRC Press, Cleveland, 1979, p. 169-175. 13.
8. Waxman S, Schreiber C: The determination of folate by use of radioactive folate and binding protein. In: Methods in Enzymology, Vitamins and Coenzymes, DB McCornick and LD Wright, Eds. Academic Press, New York, Vol. 66, 1980, p. 468-483.
9. Rubin A, Waxman S, Eds. The Leukemia Cell. CRC Press, Cleveland, 1979 (180 pages).
10. Waxman S, Scanlon KJ: Molecular biology of anticancer agents. In: Clinical Interpretation and Practice of Cancer Chemotherapy. Greenspan EM, Ed. Raven Press, New York, 1982, p. 39-52.
11. Waxman S, Qian G-X, and Liu C-K: Abnormal glycoproteins and glycosyltransferases in hepatocellular carcinoma (hepatoma) and hepatic metastases. In: Structural Carbohydrates in the Liver. H Popper, W Reutter, F Gudat and E Kottgen, Eds., MTP Press Ltd., Boston, 1982, p. 467-476.
12. Scher W, Scher BM, Waxman S: Nuclear events during differentiation of erythroleukemia cells. In: Current Concepts in Erythropoiesis, Dunn CDR, ed., John Wiley and Sons, Ltd., Chichester, 1982, p. 301-338.
13. Corrocher R, Abramson RG, King FV, Schreiber C, Waxman S: Differential binding of folates but not methotrexate (MTX) by brush border (BB) and basal lateral membranes. In: Chem. and Biol. of Pteridines, Elsevier/ N. Holland, New York, 5, 1983.
14. Scanlon KJ, Riegelhaupt R, Pallai M, Kisthard H, Kassan S, Waxman S: Altered methotrexate sensitivity in human leukemic K562 amino acid transport mutant cells. In: Chem. and Biol. of Pteridines. Elsevier, North Holland, New York 5: 7, 1983.

15. Waxman S, Scher W, Scher BM: Basic principles utilizing combination differentiation agents. In: The Sixth Internatl. Symp. for the Detection and Prevention of Cancer, 1984. (HE Nieburgs, Ed.) Alan R. Liss, Inc., New York.
16. Kane ML, Kolhouse FJ. Waxman S: Update on folate binding proteins. In: Vitamins, XII International Congress of Nutrition 1985 (TG Taylor, Ed.) J. Libbey, Brighton, U.K.
17. Ghitis J, Schreiber S, Waxman S: Folate normalizes elevated PRPP levels of folate deficient HL-60 cells. In: Pteridines and Folic Acid Derivatives: Proceedings of the 8th International Symposium, Montreal, Canada, 1986. Walter de Gruyter and Co., NY.
18. Waxman S, Rossi G, Takaku F. (eds.) of Conference Publication, Status of Differentiation Therapy in Cancer, Raven Press, New York, 1988. S Waxman and F Takaku contributed a chapter entitled "The Incorporation of Differentiation Induction Into the Design of Cancer Therapy."
19. Waxman S, Scher W, Scher BM: Basic principles utilizing combination differentiation agents. In: Developments in Preventive Oncology (HE Niebergs, ed.) Alan R. Liss Inc., New York, NY, 1988.
20. Waxman S: Review of "Tumor Cell Differentiation, Biology and Pharmacology" edited by Jarle Aarbakke, Peter Chiang and H Philip Koeffler. Humana Press, Clifton, N.J., Published in FASEB 3:180, 1989
21. Waxman S et al: Meeting Report - Third Conference on the Differentiation Therapy of Cancer, Sardinia, Italy, September 5-9, 1988 Cancer Research 50:3453-3464, 1990
22. Waxman S, Schreiber C, Gross L: Nutrition and Cancer. In: The Mount Sinai School of Medicine Complete Book of Nutrition (Eds: V Herbert and G Subak-Sharpe), Chapter 27 , pg 469-486, St. Martins Press, New York N.Y. , 1990
23. Kane M, Waxman S: Biology of Disease: The role of folate binding proteins in folate metabolism. Lab. Invest., 60:736-747 (1989). Published in "Pathology Reviews", edited by E Rubin and I Damjanov. Humana Press, Inc., Clifton, N.J. pp 39-48, 1990
24. Waxman S, Rossi G, Takaku F. (eds.) of Conference Publication, Status of Differentiation Therapy in Cancer, Volume II, Raven Press, New York 1991. S. Waxman and M. Hozumi contributed a chapter entitled "Design of Combination Differentiation Therapy" pp 347-353.
25. Waxman S, Rossi G, Takaku F. (eds.) of Conference Publication, Status of Differentiation Therapy in Cancer, Volume II, Raven Press, New York 1991. S Waxman, S Wang, W Scher and BM Scher contributed a chapter entitled "Combination Cytotoxic-Differentiation Therapy of Leukemia", 373-378.
26. Ferrari A, Waxman S: Differentiation agents in cancer therapy. in: Cancer Chemotherapy and Biological response Modifiers - Chapter 16, Annual 15, HM Pinedo, DL Longo and BA Chabner, eds. Elsevier Science B.V., pp 337-366, 1994.
27. Waxman S: Mechanisms involved in the sensitivity of acute promyelocytic leukemia (APL) to differentiation cytotoxic chemotherapy. in: Challenges of Modern Medicine - Vol. 10, Waxman S. ed. Ares Serono Symposia Publications., pp 435-442, 1996.
28. Licht JD, Waxman S: Promyelocytic leukemia zinc finger gene. In: Molecular Medicine – Vol. 5, Wiley Encyclopedia of Molecular Medicine, pp 2594-2597, 2002.

29. Jing Y, Waxman S. The design of selective and non-selective combination therapy for acute promyelocytic leukemia. In: Current Topics in Microbiology and Immunology, Vol. 313, Pandolfi PP, Vogt PK eds. Springer Publications, pp 245-269, 2007.

**Abstracts:**

1. Waxman S, Pratt P, Cuttner J, Herbert V: Evidence suggesting facilitated absorption in man of organic and inorganic iron by a substance present in depepsinized neutralized normal gastric juice in hog intrinsic factor concentrates. *Blood* 28: 1005, 1966.
2. Metz J, Kelly A, Chapin V, Waxman S, Herbert V: Studies of deranged nucleic acid synthesis in Vitamin B12-deficient human bone marrow. *Fed. Proc.* 26: 844, 1967.
3. Nossel HL, Niemetz J, Waxman S: Changes in the intrinsic system during intravascular coagulation. *Fed. Proc.* 26: 487, 1967.
4. Waxman S, Pratt P, Herbert V: Further evidence for presence in normal but not in pernicious anemia gastric juice of an "intrinsic factor" for absorption of iron in hemoglobin. *Clin. Res.* 15: 245, 1967.
5. Waxman S, Goodfriend T, Herbert V: Angiotensin assay and assessment of free iodide contamination using dilute coated charcoal. *Clin. Res.* 15: 457, 1967.
6. Waxman S, Metz J, Herbert V: Deranged DNA synthesis in megaloblastic anemia - accentuation by methionine; improvement by homocysteine. *J. Clin. Invest.* 47: 100a, 1968.
7. Carmel R, Waxman S, Epstein B, Rausen A, Jeffries G, Herbert V: Acquired selective malabsorption of B12 in a family. XIIth Intl. Congr. of Hemat., New York, N.Y. Sept., 1968.
8. Waxman S, Herbert V: Mechanism of pyrimethamine-induced megaloblastosis in human bone marrow. *Clin. Res.* 16: 543, 1968.
9. Waxman S, Herbert V: B12 function in "DiGuglielmo's Syndrome." *Fed. Proc.* 28: 627, 1969.
10. Waxman S, Corcino J, Herbert V: Production or accentuation of megaloblastic DNA synthesis in short-term human bone marrow cultures by glycine. *Clin. Res.* 27: 347, 1969.
11. Corcino J, Waxman S, Herbert V: Uptake of tritiated pteroylglutamic acid (3H-PGA) by human bone marrow cells in vitro. *Clin. Res.* 48: 19a, 1969.
12. Cohen S, Chikkappa G, Waxman S: Clinical usefulness of Imidazole Carboxamide for the treatment of malignant melanoma. *Amer. Coll. of Physicians*, April, 1970.
13. Waxman S, Schreiber C: DNA synthesis in short-term human tumor cell cultures. *Proc. Amer. Assoc. Cancer Res.*, April, 1970.
14. Corcino J, Krauss S, Waxman S, Herbert V: Release of Vitamin B12 binding protein (B12BP) by human leukocytes. *Fed. Proc.*, March, 1970.
15. Waxman S, Schreiber C, Herbert V: Patterns of DNA-thymine synthesis in short-term tumor cell cultures. *Clin. Res.* 18:477, 1970.
16. Corcino J, Waxman S, Rubin AD, Herbert V: Selective suppression by Ethanol of RNA synthesis in human hematopoietic cells in vitro: Fact or artifact? *J. Clin. Invest.* 49: 22a, 1970.
17. Waxman S, Schreiber C, Herbert V: Measurement of serum folate levels by radioisotope dilution assay. *Blood*, Dec. 1970.

18. Waxman S, Hellman M: Enhancement of Cytosine Arabinoside (ARA- C) activity by tetrahydrouridine (THU) in human bone marrow. *Clin. Res.* 19: 434, 1971.
19. Waxman S, Schreiber C: Characteristics of folic acid-binding macromolecular factor (FABP) in folic acid (FA) deficient serum. *Blood*, Dec., 1971.
20. Waxman S: Mechanism of Trimethoprim induced deranged folic acid metabolism in human bone marrow. *Clin. Res.* 19: 434, 1971.
21. Waxman S, Schreiber C: Further studies of serum folic acid binding protein (FABP). *Amer. J. Clin. Nutr.* 25: 450, 1972.
22. Waxman S, Schreiber C: Measurement of serum folate and folic acid binding protein by 3H-PGA radioassay. *Clin. Res.* 20: 572, 1972.
23. Waxman S, Gilbert HS: A novel Vitamin B12-binding protein in serum from two patients with hepatoma. *Clin. Res.* 20: 572, 1972.
24. Waxman S, Schreiber C: Uptake of folates by HeLa cells: The role of folic acid binding protein (FABP). *Blood*. Dec., 1972.
25. Waxman S, Schreiber C: Similarities in the folic acid binding protein (FABP) of various tissues. *Clin. Res.* 11: 571, 1973.
26. Price PN, Gabelman N, Hirschhorn K, Waxman S: In vitro hybridization of C-type viral RNA to human DNA. *J. Clin. Invest.* 52: 67a, 1973.
27. Waxman S, Schreiber C: Properties of purified folic acid binding proteins (FABP). *Blood.* 42: 120, 1973.
28. Waxman S, Burger RL, Gilbert HS, Allen RH: Purification and properties of a B12 binding protein associated with adolescent hepatoma. *Blood.* 129, 1973.
29. Waxman S, Burger RL, Gilbert HS, Allen RH: Hepatoma B12 binding protein HB12BP), a novel glycoprotein with increased sialic acid content. *Proc. Amer. Assoc. Cancer Res.*, p. 67, March, 1974.
30. Gabelman N, Waxman S, Douglas SD: Oncornavirus-like particles in cultures of human tumor cells co-cultivated with rat cells. *Clin. Res.* 22: 484, 1974.
31. Bruckner HW, Schreiber C, Waxman S: Interaction of chemotherapeutic agents with methotrexate as measured by the deoxyuridine (DU) suppression test. *Clin. Res.* 22: 480, 1974.
32. Greenberg ML, Waxman S: Sequential use of methotrexate (MTX), folinic acid (FA) and cytosine arabinoside (ARA-C) in the treatment of acute leukemia. *Intl Congress of Hemat.*, 1974.
33. Waxman S, Schreiber C: Folate radioassay. *Clin. Chem.* 20: 725, 1974.
34. Waxman S, Schreiber C: Isolation and characterization of folate binding proteins (FABP) from human milk by affinity chromatography. *Blood*. Dec., 1974.

35. Waxman S, Schreiber C: Separation of folate binding proteins (FABP) from bovine-lactoglobulin (BLG). *Blood*. Dec., 1974.
36. Waxman S, Schreiber C: Exaggerated elevations of radioassayable serum folate levels following heat extraction of "bound oxidized folates." *Blood*. Dec., 1974.
37. Rubinoff M, Schreiber C, Waxman S: Isolation and characterization of folate binding protein (FABP) from goat milk by affinity chromatography. *Fed. Proc.* 34: 904, 1975.
38. Gabelman N, Waxman S, Smith W, Douglas SD: Appearance of C- type virus particles after co-cultivation of human tumor and rat (XC) cells. *Proc. Amer. Assoc. Cancer Res.* 129, May, 1975.
39. Gabelman, N., Ong, S. and Waxman, S.: Co-cultivation of human tumor and XC cells as a method for the induction of C-type particles. *Clin. Res.* 23: 273, 1975.
40. Waxman S, Schreiber C: Folic acid binding protein (FABP) membrane function and role in intracellular folyl polyglutamate distribution. *Clin. Res.* 23: 284a, 1975.
41. Waxman S, Rubinoff M, Schreiber C: Immunologic studies on folate binding protein. *Blood*, 114: 1975.
42. Waxman S, Schreiber C, Helson L: Further studies on the origin of hepatoma B12 binding protein. *Blood*, 131: 1975.
43. Waxman S, Schreiber C, Helson L: Hypersialylation; a mechanism for accumulation of acid glycoproteins in malignancy. *Proc. Amer. Soc. Cancer Res.* 76: 1976.
44. Bruckner H, Waxman S: Effect of methotrexate on L1210 leukemia in vitro as a function of MTX, leucovorin and dihydrofolate reductase. *Proc. Amer. Soc. Cancer Res.* 158: 1976.
45. Waxman S, Schreiber C, Liu CK: Characteristics and possible clinical significance of the large molecular weight folate binding protein. (L-FABP). *Clin. Res.* 24: 233, 1976.
46. Guilford H, Schreiber C, Sheppard R, Rose M, Waxman S: Measurement of serum folate by <sup>75</sup>Se-folate radioassay. *Blood*, Dec., 1976.
47. Gabelman N, Smith W, Geller S, Prystowsky M, Ong S, Waxman S: Induction of a reticulum cell sarcoma by a primate RNA tumor virus. (v-L104) induced by co-cultivation of rat and human tumor cells. *Blood*, Dec., 1976.
48. Waxman, S., Rubinoff, M., Greenspan, E.M. and Bruckner, H.: Interaction of methotrexate and 5-fluorouracil; effect on de novo DNA synthesis. *Proc. Amer. Ass. Cancer Res.* 17: 157, 1976.
49. Rubinoff M, Abramson R, Schreiber C, Waxman S: The effect of FABP on plasma transport of folates. *Blood*, Dec., 1976.
50. Gabelman N, Robinson A, Ong S, Waxman S: Antibodies in human sera to an oncornavirus ((v-L104) isolated from human tumor cells co- cultivated with rat cells. *Proc. Amer. Assoc. Cancer Res.*, 1977.
51. Bruckner HW, Wagle A, Gabelman N, Waxman S: Effect of leucovorin (LV), methotrexate (MTX), metroprine (DDMP) in normal and MTX resistant friend leukemia cells (FLC). *Clin. Res.*, 1977.

52. Rubinoff M, Abramson R, Schreiber C, Waxman S: Differences in folate transport and distribution caused by folate binding protein (FABP). *Clin. Res.*, 1977.
53. Liu CK, Schreiber C, Schmied R, Waxman S: Novel glycoproteins in hepatocellular carcinoma (hepatoma). *Proc. Amer. Assoc. Cancer Res.* 285, 1977.
54. Rubinoff M, Abramson R, Schreiber C, Waxman S: The fate and role of folate binding protein (FABP) in the plasma transport of folates and anti-folates. *Blood.* 69: 1977.
55. Waxman S, Schreiber C, Sharon B, Gabelman N, Gilbert H: Folate binding proteins (FABP) in human blood cells. *Blood.* Nov., 1977.
56. Bruckner HW, Waxman S: Antimetabolic differences of 3 anti- folates in vitro: Methotrexate (MTX), Metoprine (DDMP), and Baker's Triazine (BT). *Proc. Amer. Assoc. Cancer Res.* 19: 175, 699, 1978.
57. Waxman S, Bruckner H, Wagle A, Schreiber C: Potentiation of 5- fluorouracil (5-FU) antimetabolic effect by Leucovorin (LV). *Proc. Amer. Assoc. Cancer Res.* 69: 149, 1978.
58. Gilbert HS, Waxman S: Vitamin binding protein release during the initial phase of phagocytosis. *Clin. Res.* 26: 3, 581A. 1978.
59. Zalos P, Waxman S, Schreiber C, Kyner D, Mendelsohn N, Christman J, Acs G: 2-deoxyglucose (2-DG) decarboxylation by phagocytic leukocytes in the presence of 12-0-tetradecanoyl phorbol- 13-acetate. *Blood* 52: suppl. 1, 130, 1978.
60. Liu CK, Schmied R, Waxman S: Abnormal glycosyltransferases in human hepatoma. *Proc. Amer. Assoc. Cancer Res.* 15: 285, 1979.
61. Nichols P, Benenson TJ, Stimmel B, Waxman S. The ability of an intensive educational exposure to upgrade skills of American students from foreign medical schools upon entry into the American medical education system. *Clin. Res.*, 27: 1979.
62. Liu CK, Schmied R, Schreiber C, Waxman S. Phorbol-12 Myristate-13-Acetate (PMA) release of glycosyltransferase in human phagocytic leukocytes. *XIth Intl Congr. of Biochem.* p. 491, 1979.
63. Liu CK, Schmied R, Waxman S: Patterns of glycosyltransferase release in human blood cells by 12-0-tetradecanoyl-phorbol-13-acetate (TPA). *Blood* 197, 88a, 1979.
64. Grossowicz N, Waxman S: Microbial transformation of homofolate. *Fed. Proc.* 39: 3, 1980.
65. Grossowicz N, Waxman S: A modified folate bioassay using a cryoprotected *L. casei* inoculum. *Clin. Res.* 28: 595A, 1980.
66. Scher B, Scher WH, Waxman S: Alterations in DNA ligase and deoxyribonuclease (DNAase) I activities in mouse erythroleukemia (MEL) cells during dimethyl sulfoxide (DMSO)-induced differentiation. *Proc. Amer. Assoc. Cancer Res.* 21: 45, 180, 1980.
67. Scanlon KL, Waxman S: Adaptative methionine transport and biosynthesis: An alternative mechanism for resistance to methotrexate (MTX) in mouse leukemia L1210 cells. *Amer. Soc. Biol. Chem.* 39: 1908, 1980.



68. Scanlon KJ, Waxman S: Inhibition of methionine transport by methotrexate (MTX) in mouse leukemia L1210 cells. *Amer. Assoc. Cancer Res.* 21: 284, 1980.
69. Scanlon KJ, Schreiber C, Waxman S: Modulation of methionine transport by physiologic folates and by methotrexate (MTX) in human lymphocytes. *J. Clin. Invest.* 28: 527A, 1980.
70. Scher WH, Waxman S: Further evidence that there are different biochemical mechanisms for the induction of hemoglobin synthesis in mouse erythroleukemia cells. *Intl Soc. Hemat.* 88, 1980.
71. Waxman S, Scanlon KJ, Schreiber C: Folate binding protein acts as a non-competitive inhibitor of dihydrofolate reductase. *Intl Soc. Hemat.* 291, 1980.
72. Berman LB, Liu CK, Orlowski J, Kilburn KH, Waxman S, Orlowski M: A profile of proteinase activity in extracts of human monocytes, lymphocytes, neutrophils, and platelets. *Clin. Res.* 23: 3, 1980.
73. Berman LB, Perez F, McNamee M, Waxman S, Liu CK: High elastase levels in normal cultured human blood monocytes. *Amer. Thoracic Soc.* 1981.
74. Scanlon KJ, Pallai ME, Berkowitz K, Waxman S: Different membrane transport properties in normal and chronic lymphocytic leukemia (CLL) lymphocytes. *Amer. Fed. Clin. Res.* 29: 440a, 1981.
75. Liu CK, Schmied R, Waxman S: Glycosyltransferase changes during DMSO-induced differentiation of HL-60 cells. *Clin. Res.* 29: 520A, 1981.
76. Scanlon KJ, Pallai ME, Waxman S: Evidence for a shared methotrexate-methionine membrane transport protein(s) in human lymphocytes. *J. Supramolecular Structure and Cellular Biochem. suppl.* 4: 137, 1981.
77. Liu CK, Schmied R, Scher W, Waxman S: Alterations in glycosyltransferase levels in mouse erythroleukemia (MEL) cells during DMSO-induced differentiation. *Amer. Assoc. Clin. Res.* 1982.
78. Scanlon KJ, Berkowitz K, Pallai ME, Waxman S: Inhibition of methionine transport by methotrexate (MTX) in stimulated normal human lymphocytes. *Amer. Assoc. Cancer Res.* 22: 1016, 1982.
79. Scanlon KJ, Pallai M, Berkowitz K, Saketos Riegelhaupt R, Waxman S: The role of the amino acid transport systems in mitogen activated human lymphocyte growth. *Cellular and Molecular Biology of Hematopoietic Stem Cell Differentiation*, Toronto, Sept. 1982.
80. Scher BM, Yeh H, Scher W, Waxman S: Changes in G-actin and F- actin pools during mouse erythropoiesis. *Blood* 58: 5; Suppl. 1, 101a, 1982.
81. Scanlon KJ, Lachman L, Wang-Iverson P, Pallai M, Berkowitz K, Riegelhaupt R, Waxman S: Alteration of amino acid transport systems in human lymphocytes stimulated by interleukin I (IL-1). *Blood* 58: suppl. 1, 5, 115a, 1982.
82. Liu CK, Schmied R, Schreiber C, Waxman S: Cell-type related alterations in glycosyltransferase levels in human promyelocytic leukemia (HL-60) cells associated with various inducers of differentiation. *Am. Assoc. Cancer Res.* 23: 1982.
83. Scanlon KJ, Safirstein R, Guttenplan JB, Thies HL, Waxman S: Inhibition of the ASC amino acid transport system by Cis- platin (cisPt) derivatives in L1210 cells. *Am. Assoc. Cancer Res.* 23: 167, 1982.

84. Scanlon KJ, Lachman L, Wang-Iverson P, Pallai M, Waxman S: Influence of methotrexate (MTX) on membrane transport systems in growing human lymphocytes. *J. Cellular Biochem. Suppl.* 6: 382, 1982
85. Scanlon KJ, Lachman L, Wang-Iverson P, Pallai M, Waxman S: The role of methotrexate (MTX) on membrane transport systems in growing human lymphocytes. *J. Supramolecular Structure and Cellular Biochem. Suppl.* 6, 382, 1982.
86. Scanlon KJ, Lachman L, Berkowitz K, Pallai M, Waxman S: Normal and leukemic "T" cell lymphocyte response to interleukins (IL- 1). 13th Intl Cancer Congr., Seattle, 110: 1824, 1982.
87. Scanlon K, Ohnuma T, Lo RJ, Nichol CA, Waxman S, Greenspan EM, Holland JF: Effects of 2,4-diamino-6-(2,5-dimethoxybenzyl)- 5-methylpyrido (2,3-D) pyrimidine (BW301U) on methotrexate (KTX) resistant human acute lymphoblastic leukemia (All) cell lines. *Amer. Soc. Clin. Oncology* 1: 12, 1982.
88. Corrocher R, Abramson RG, King VF, Schreiber C, Waxman S: Greater uptake of folate (FA) by brush border (BB) than by basolateral (BL) membrane vesicles from rat kidney. *Clin. Res.* 30: 539a, 1982.
89. Scher W, Waxman S. Effects of dexamethasone (DEX) and phorbol myristate acetate (PMA) on the induction of differentiation in mouse erythroleukemic (MEL) cells by dimethyl sulfoxide (DMSO) and other compounds. *N.Y. Aca. of Sci. Symp. on Differentiation*, Sept., 1982.
90. Waxman S, Corrocher R, Schreiber C: Temperature related folate displacement and exchange from folate binding protein (PBB). *Blood* 60: 5, suppl. 1, 1982.
91. Scher W, Scher BM, Waxman S: Proteases stimulate mouse erythroleukemia cell (MEL) differentiation and multiplication. *Blood* 60: 5, Suppl. 1, 91a, Nov., 1982.
92. Waxman S: The Rationale for Biological Response Modifiers. *Proc. Chemo. Found. Symp.* V Nov., 1982.
93. Scanlon KJ, Lachman L, Gross R, Waxman S: Normal and leukemic "T" cell lymphocyte response to Interleukins (IL-1). 15th Intl. Leucocyte Culture Conf. Dec., 1982.
94. Gross RB, Scanlon KJ, Kisthard H, Waxman S: Membrane transport properties of L1210 cells resistant to cisplatin. *Amer. Assoc. Cancer Res.* 24: 281, 1983.
95. Scher W, Scher BM, Waxman S: Proteases and low molecular weight inducers act synergistically to stimulate mouse erythroleukemia (MEL) cell differentiation. *Fed. Proc.* 42: 1034, 1983.
96. Scher W, Scher BM, Waxman S: Proteases stimulate mouse and human cell differentiation and proliferation. *Proc. Amer. Assoc. Clin. Res.* 74: 20, 77, 1983.
97. Qian GX, Liu CK, Waxman S: Abnormal isoelectricfocusing patterns of serum galactosyltransferase in patients with liver neoplasia. *Clin. Res.* 31: 2, 510a, 1983.
98. Scher BM, Scher W, Waxman S: DNA ligase activity in extracts of mouse erythroleukemia (MEL) cells during differentiation. *Fed. Proc.* 42: 1034, 4348, 1983.
99. Scher W, Scher BM, Waxman S: Proteases induce erythrodifferentiation and growth in vitro. *Fed. Proc.* 42: 1768, 64, 1983.

100. Scher BM, Scher W, Schreiber C, Waxman S: DNA ligase: a biochemical marker for differentiation and commitment in Friend-virus infected mouse erythroleukemia (MEL) cells. *Blood* 62: 5, Suppl. 1, 154a, 1983.
101. Waxman S, Schreiber C: In vitro induction of differentiation of bone marrow by chemotherapeutic agents in myeloproliferative disorders. *Blood* 62: 5, Suppl. 1, 154a, 1983.
102. Scher W, Scher BM, Hellinger N, Waxman S: Proteases stimulate K562 cell erythrodifferentiation and cell yield, but not commitment to terminal cell division. *Blood* 62: 5, Suppl. 1, 154a, 1983.
103. Shao GY, Waxman S: Phorbol diester induced phospholipid/Ca<sup>2+</sup> dependent protein kinase (protein kinase C) changes in HL-60 cells. *Proc. Amer. Assoc. Cancer Res.* 25: 175, 1984.
104. Scher BM, Scher W, Waxman S: Protease-induced differentiation in mouse erythroleukemia (MEL) cells: lack of a serum requirement. *Fed. Proc.* 43: 6, 1789, abst. 2180, 1984.
105. Scher W, Hellinger N, Waxman S: Variations in hemoglobin (Hb) types induced by proteases in mouse erythroleukemia (MEL) and human K562 cells. *Fed. Proc.* 43: 6, 1790, abst. 2181, 1984.
106. Corrocher R, Morittu C, Lunardi G, Abramson RG, Waxman S: Mechanism of displacement of folate from the cell membrane of renal tubule. 7th Meeting Intl. Soc. Haemat., Barcelona, 9, 1983.
107. Waxman S: Concept of differentiation chemotherapy. *Chemotherapy Fdn. Symp.* Nov., 1984.
108. Waxman S, Schreiber C, Scher BM, Scher W: Basic principles utilizing combination differentiation agents. ISPO Symp., Intl. Soc. Preventive Oncol. Vienna, Nov., 1984.
109. Scher W, Scher BM, Hellinger N, Gersten G, Cohen T, Waxman S: Variations in the hemoglobin (Hb) type induced in mouse erythroleukemia (MEL) cells are time and concentration dependent as well as agent specific. *Blood* 64 (5) Suppl. 1, 64a, abst. 168, 1984.
110. Kane MA, Schreiber C, Waxman S: Folate binding proteins in human granulocytic cells vary with cellular differentiation. *Blood* 64:68a, 1984.
111. Kane MA, Kolhouse JF, Schreiber C, Waxman S: Human cancer cells with an extremely low folate requirement. *Clin. Res.* 33:12, 577A, 1985.
112. Kane MA, Kolhouse JF, Schreiber C, Waxman S: Current status of the role of folate binding proteins. XIII International Congress of Nutrition, Brighton, England, August 1985.
113. Kane MA, Roth E, Raptis G, Waxman S: Phosphoribosyl pyrophosphate (PRPP) levels are markedly elevated & sensitivity to methotrexate (MTX) and 5-fluorouracil (5FU) is altered in malignant cells cultured in physiologic folate. *Amer. Soc. Hematology, 27th Annual Meeting, New Orleans, La., 1985.*
114. Kane MA, Antony AC, Kolhouse JF, Waxman S: Folate binding protein (FBP) regulates folate uptake in human epidermoid carcinoma (KB) cells. *Amer. Soc. Hematology, 27th Annual Meeting, New Orleans, La., 1985.*
115. Scher W, Scher BM, Hellinger N, Waxman S: Aprotinin (APR) alters hexamethalene bisacetamide (HMBA)-induced hemoglobin (Hb) phenotype in differentiating mouse erythroleukemia (MEL) cells. *Proc. Am. Assoc. Cancer Res.* 188(76), 1986.

116. Kane MA, Roth E, Raptis G, Waxman S: Folate levels in cultured malignant cells modulate phosphoribosylpyrophosphate (PRPP) levels and sensitivity to 5-fluorouracil (FU) and methotrexate (MTX). *Proc. Am. Assoc. Cancer Res.* 1200(46), 1986.
117. Scher BM, Scher W, Pino M, Waxman S: The effect of hemin on the ATP-dependent DNA ligase activity of Friend virus-infected mouse erythroleukemia (MEL) cells. *Proc. Am. Assoc. Cancer Res.* 187(76), 1986.
118. Slosberg EA, Scher BM, Scher W, Josephson S, Waxman S: Localization of the site of action of protease inducers of erythroid differentiation of mouse erythroleukemia (MEL) cells to the cell surface. *Exper. Hematol.* 14(6) 442, 1986.
119. Ghitis J, Schreiber W, Waxman S: Folate Normalizes elevated PRPP levels of folate deficient HL60 cells. 8th International Symposium, Pteridine and Folic Acid Derivatives, Montreal, Canada, June 15-20, 1986.
120. Scher BM, Scher W, Waxman S: The fate of DNA ligase activity during differentiation of mouse erythroleukemia cells. First Conference on Differentiation Therapy, Sardinia, Italy, August 30-September 03, 1986.
121. Scher W, Scher BM, Slosberg EA, Josephson S, Waxman S: Localization of the site of action of protease inducers of erythroid maturation of mouse erythroleukemia cells to the cell surface. First Conference on Differentiation Therapy, Sardinia, Italy, August 30 September 03, 1986.
122. Waxman S: Differentiation Chemotherapy. *Cancer Investigation* 4:5, 1986.
123. Scher BM, Scher W, Waxman S: Therapeutic implications of hemin inhibition of ATP-dependent DNA ligases. *Am. Assoc. Cancer Res.* 28:1763, 1987.
124. Finley A, Scher W, Waxman S: Changes in levels of phosphorylation of plasma membrane proteins in mouse erythroleukemia (MEL) cells during hexamethylene bisacetamide (HMBA)-induced differentiation. *Am. Assoc. Cancer Res.* 28:103, 1987.
125. Waxman S: Cancer Chemotherapy - is cytotoxicity the answer? International Society of Differentiation, 5th International Meeting, August 3-7, 1987, Boulder, CO, p. 41L.
126. Chou JL, Coppola G, Shen ZX, Schreiber C, Waxman S: B- Casein and K6, K14 cytokeratin gene expression in primary cultures (PC) of mouse mammary tumor cells (MMTC). *Proc. Am. Assoc. Cancer Res.* 29:42 #167, 1988.
127. Wu H, Scher BM, Scher GS, Scher W, Waxman S: Marked alterations in carbohydrate metabolism of leukemia cells during in vitro differentiation. *Clin. Res.* 36:3, 590A, 1988
128. Scher BM, Scher W, Waxman S: Studies on the DNA ligase of mouse erythroleukemia (MEL) cells: therapeutic implications. *Ann. N.Y. Acad. Sci.* (17) 1988
129. Scher BM, Scher W, Waxman S: Hemin, A DNA Ligase Inhibitor, enhances the cytotoxicity of DNA-damaging agents. Mt. Sinai Research Day, 1987.
130. Scher W, Scher BM, Hellinger N, Waxman S: Benzyl alcohol (BA) reduces the accumulation of hemoglobin minor (Hb mn) compared to hemoglobin major (HB mj) in mouse erythroleukemia (MEL)

cells induced to differentiate by dimethyl sulfoxide (DMSO) and hexamethylene bisacetamide (HMBA). Ann. N.Y. Acad. Sci. (18) 1988

131. Scher BM, Wu H, Scher W, Waxman S: Changes in carbohydrate metabolism of mouse erythroleukemia (MEL) cells and human promyelocytic (HL-60) cells during the induction of in vitro differentiation. The Third Conference on Differentiation Therapy, Sardinia, Abs. #78, Sept. 5- 9, 1988.
132. Scher BM, Scher W, Waxman S: Inhibition of malignant cell growth by combinations of hemin and DNA-damaging agents. The Third Conference on Differentiation Therapy, Sardinia Abst. #107, Sept. 5- 9, 1988.
133. Waxman S: The incorporation of differentiation induction into the design of cancer therapy. Chemotherapy Foundation Symposium VIII, Nov. 16- 18, 1988 in Cancer Invest. 6:1-2, 1988.
134. Shen ZX, Chou JL, Tan IJ, Waxman S: In vitro regulation of mouse mammary tumor epithelial cell (MMTC) growth by transforming growth factors (TGFs) and extracellular matrix (ECM). Amer. Asso. Cancer Res., May, 1989.
135. Chou JL, Shen ZX, Stolfi RL, Martin DS, Waxman S: Interaction of mouse mammary tumor epithelial cells (MMTCs) with extracellular matrix (ECM) in vitro: modulation of growth and B-casein gene expression. Amer. Asso. Cancer Res. May, 1989.
136. Scher BM, Scher W, Waxman S: Enhancement by hemin of the cytotoxicity caused by hyperthermia and certain DNA-damaging agents. Amer Asso. Cancer Res. May, 1989.
137. Waxman S: Differentiation therapy; basic aspects and clinical progress. Chemoprevention of upper aerodigestive tract cancers - upper aerodigestive cancer working group workshop, sponsored by the organ systems coordinating center of the organ systems program, National Cancer Institute, Washington, D.C. March 16, 1989
138. Waxman S, Scher BM, Hellinger N, Scher W: Combination cytoreductive differentiation therapy with 5-FU and HMBA. MSSM, Seventh Annual Research Day, September 12, 1989.
139. Waxman S: Combination cytotoxic differentiation therapy of leukemia with 5-fluorouracil (5-FU), Leucovorin (LV) and hexamethylene bisacetamide (HMBA). Anniversary Congress (Hematology) Johannesburg, South Africa, October 15-20, 1989.
140. Waxman S, Scher BM, Hellinger N, Waxman S: Combination cytotoxic- differentiation therapy with 5-fluorouracil (5-FU) and hexamethylene bisacetamide (HMBA). Blood 74:#7 Suppl. 1, pg 234a, #877, 1989.
141. Scher W, Eto Y, Ejima D, Den T, Svet-Moldavsky IA: Phorbol ester-treated primary human acute myeloid leukemia (AML) cells release G- CSF, GM-CSF and erythroid differentiation factor (EDF) into serum-free culture medium. Proc. Amer. Asso. Cancer Res. 31:29 #168, 1990.
142. Waxman S, Wang S, Tan I, Scher W: Combination cytotoxic differentiation therapy with 5-fluorouracil, leucovorin and hexamethylene bisacetamide. Proc. Amer. Asso. Cancer Res. 31:430 #2551, 1990
143. Deak G, Scher W, Pizzella T, Waxman S, Acs G.: A transacting factor that binds a c-myc sequence is induced during HL-60 cell differentiation. FASEB Journal 4:#7 A2092 #2312, 1990

144. Waxman S: Combination cytoreductive differentiation cancer therapy. Sixth International Conference on Differentiation and Neoplasia. International Society of Differentiation. Vancouver, B.C. ,July 29 to August 2, 1990.
145. Waxman S, Wang S, Scher W, Scher B: Combination cytotoxic differentiation therapy of leukemia. Fourth Conference on the Differentiation Therapy of Cancer. Tokyo, Japan, Nov 4-9, 1990
146. Waxman S: Combination cytotoxic-differentiation cancer therapy. 1st International Symposium of Hiroshima Cancer Seminar. Hiroshima, Japan. November 9-10, 1990.
147. Waxman S, Weinrauch S, Scher W: Design of combination cytotoxic-differentiation therapy of acute promyelocytic leukemia. Amer. Assoc. Cancer. Res. Houston, TX May 15-18, 1991.
148. Lazega D, Waxman S: Post-translational change in retinoic acid receptor during treatment of F9 cells with retinoic acid. Amer. Assoc. Cancer Res. Houston, TX May 15-18, 1991.
149. Mira-y-Lopez R, Waxman S: On the mechanism whereby retinoic acid potentiates the inductive effect of cAMP on plasminogen activator synthesis in a mammary tumor cell line. Amer. Assoc. Cancer Res. Houston, Tx May 15-18, 1991.
150. Waxman S, Weinrauch, Huang Y: An increase in non-viable differentiated leukemia cells following combination cytotoxic-differentiation therapy for acute promyelocytic leukemia. Ninth Annual Research Day, Oct. 22, 1991 Mt. Sinai School of Medicine.
151. Waxman S, Huang Y: Selective therapeutic apoptosis results from combination cytotoxic differentiation therapy of leukemia. Blood 78:10 Suppl. 1 pg 47a, 1991
152. Waxman S: Combination cytotoxic-differentiation therapy of leukemia. (Presented at the Chemotherapy Foundation Symposium, NYC 11/7/91. Cancer Investigation 10: Supplement 1, pg 1-2 1992.
153. Chang TJ, Scher BM, Olmedo R, Waxman S, Scher W: Inhibition of GATA-1 function by glucocorticoid receptor (GR) at the level of beta-globin genes: Relationship to glucocorticoid (GC) inhibition of MELC differentiation. Amer. Asso. Canc. Res. 33:233 #2159, March, 1992.
154. Chang TJ, Scher BM, Olmedo R, Waxman S, Scher W: Effects of GATA-1 transacting factor and glucocorticoid receptor (GR) on friend leukemia virus (FLV) long terminal repeat (LTR)-directed gene expression: The erythrotropism of FLV may be due to GATA-1. Amer. Asso. Canc. Res. 33:233 #2342, March 1992.
155. Zelent AZ, Chen Z, Chen S-J, Chen A, Tong J-H, Geng T-J, Waxman S: A chimeric mRNA between RAR-alpha and an unknown gene on chromosome 11q in APL with a variant t(11;17) translocation. Amer. Asso. Canc. Res. 33:233 #1398, March 1992.
156. Chang TJ, Scher BM, Olmedo R, Waxman S, Scher W: Regulation by GATA-1 and glucocorticoid receptor (GR) of mouse B-Major (MJ) and -Minor (MN) globin and friend virus (FLV) expression. Int. Soc. of Diff. Helsinki, Finland, July 1992.
157. Gallagher R, Etkind P, Pena S, Oiu L, Rao S, Sagavadan G, Waxman S, Zelent A, Wiernik P: Aberrant PML-RAR alpha/PML fusion products in a subset of acute promyelocytic leukemia (APL) patients. Amer. Soc. Hematolo. December 1992.

158. Chen S-J, Zelent A, Tong J-H, Wand Z-Y, Derre J, Berger R, Licht J, Waxman S, Chen Z: Rearrangement of the RAR alpha and a novel zinc finger gene (PLZF) resulting from t(11;17) (q23;21) in a patient with acute promyelocytic leukemia (APL). *Amer. Soc. Hemat.* December 1992.
159. Najfeld V, Chen A, Scalise A, Ambinder E, Fernandez G, Waxman S: Myelodysplastic syndrome (MDS) transforming to a variant acute promyelocytic leukemia (APL) with trisomy and rearrangement of chromosome 11. *Amer. Soc. Hemat.* December 1992.
160. Chen S-J, Chen Z, Tong J-H, Chen A, Wang ZY, Le Coniat M, Berger R, Zelent A, Waxman S: The retinoic acid receptor alpha (RARA) gene is fused with a transcription unit on chromosome 11q in an acute promyelocytic leukemia (APL) patient with variant t(11:17) translocation. *Biomed. and Pharmacotherapy* 46:290 (#103), 1992.
161. Gallagher R, Zelent A, Zgang S, Peng S, Rao S, Sagayadan G, Waxman S, Wiernik P: Differential regulation of PML-RAR alpha and RAR alpha 1 mRNA's following trans-retinoic acid (tRA) treatment of acute promyelocytic leukemia (APL) cells. *Biomed. and Pharmacotherapy* 46:292 (#109), 1992.
162. Zelent A, Chen SJ, Chen Z, Brand N, Tong JH, Geng P, Yu HQ, Chen A, Waxman S: Novel chimeric mRNA expressed in APL patient with a variant t(11:17) reciprocal chromosomal translocation between RAR-alpha and previously uncharacterized TFIIIA-like zinc-finger encoding gene on chromosome 1123. *Biomed. and Pharmacotherapy* 46:295 (#114), 1992.
163. Waxman S, Huang Y: Synergistic induction of selective apoptosis by combination cytotoxic differentiation therapy of leukemia. *Cancer Investigation Supp.*1:11:35, 1992.
164. Chang TJ, Scher BM, Waxman S, Scher W: Possible mechanism of glucocorticoid (Gc) inhibition of mouse (m) erythroleukemia (MEL) cell erythrodifferentiation (ED). *The FASEB Journal*, 7:3 A 167 (#966), 1993.
165. Huang Y, Waxman S: Synergistic introduction of apoptosis (APO) by combination cytotoxic-differentiation therapy (CCDT) *Proc. Amer. Assoc. Cancer Res.* 34:293, 1993.
166. Najfeld V, Chen A, Scalise A, Ambinder E, Fernandez G, Waxman S: Trisomy and rearrangement of chromosome 11 in a variant acute promyelocytic leukemia (APL). 8th Symposium. *Molecular Biology of Hematopoiesis.* Basel, Switzerland, July 9-13, 1993.
167. Chen Z, Licht JD, Zelent A, Chen SJ, Chen A, Wu Y, Miller WH, Zelenetz A, Goy A, DeBiasio A, Scott A, Willman C, Head D, Chomienne C, Waxman S: Clinical and molecular characterization of the acute promyelocytic leukemia (APL) associated with t(11;17) and PLZF-RAR-alpha fusion. *Amer. Soc. Hematology*, Dec. 1993.
168. Licht JD, Chen Z, Zelent A, Chen SJ, Chen A, Li J, Wu Y, Melnick A, Shaknovich R, English MA, Waxman S: Functional characterization of the promyelocytic leukemia zinc finger (PLZF) protein and its fusion proteins with RAR-alpha. *Amer. Soc. Hematology*, Dec. 1993.
169. Chen A, Hellinger N, Wu Y, Licht JD, Scher W, Waxman S: Modulation of PLZF gene expression in HL-60 and NB4 human leukemia cells during differentiation induction by all trans retinoic acid (ATRA), vitamin D3 (VD3) and hexamethylene bisacetamide. *Proc. AACR* 35:87 (# 517), 1993.
170. Jing Y-K, Bleiweiss I, Brower S, Tartter P, Waxman S, Mira-y-Lopez R: Retinoic acid receptor (RAR) beta induction and cell proliferation regulation by retinoic acids (RA) in human breast cancer. *Proc. AACR*, 35:270 (#1611), 1993.

171. Licht JD, Melnick A, English MA, Shaknovich R, Li J, Reddy JC, Chen Z, Zelent A, Chen S-J, Chen A, Wu Y, Waxman S: Characterization of the promyelocytic leukemia zinc finger protein and its fusion protein with the retinoic acid receptor alpha. *Proc. AACR* 35:86 (#516), 1993.
172. Jing Y-K, Waxman S: Structural requirements for growth inhibition and differentiation -induction of DS19 mouse erythro leukemia (MEL) cells by isoflavones. *Proc. AACR* 35:413 (#2462), 1993.
173. Melnick AM, English MA, Shaknovich R, Chen Z, Waxman S, Licht JD: Altered DNA binding activity of the retinoic acid receptor-alpha (RAR-alpha) when fused to the PLZF protein in t(11;17) acute promyelocytic leukemia (APL). *Clin. Res.* 42: 126A (#2), 1994.
174. Waxman S: Differentiation therapy of cancer from a clinical perspective. International Society of Differentiation. Tokyo, Japan, 1994.
175. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBiasio A, Miller WH, Zelenetz AD, Willman CL, Chen, Chen, S-J, Zelent A, Macintyre E, Veil A, Cortes J, Kantarjian H, Waxman S: Acute promyelocytic leukemia associated with t(11;17) is a discrete syndrome that fails to respond to retinoic acid. *Blood* 84:10 Suppl. 1, 139a (#1500), 1994.
176. Shaknovich R, English MA, Melnick A, Li J-Y, Weiland S, Tarcsafalvi A, Waxman S, Licht JD: The Chimeric PLZF-RAR alpha fusion protein of t(11;17) APL is an aberrant RAR that interferes with wild type RAR alpha function. *Blood* 84:10 Suppl. 1, 441a (#1748), 1994.
177. Li J-Y, English MA, Bisht S, Waxman S, Licht JD: DNA Binding and transcription regulation by the promyelocytic leukemia zinc finger protein. *Blood* 84:10 Suppl. 1, 40a (152), 1994.
178. Cook M, Gould A, Reid A, Licht JD, Shaknovich R, Li Y-L, Davies J, Strutt P, Waxman S, Krumnlauf R, Zelent A: Developmental expression of the murine homologue of the promyelocytic leukemia zinc finger gene. *Blood* 84:10 Suppl. 1, 42a (158), 1994.
179. Li JY, English M, Waxman S, Licht J: Functional analysis of the promyelocytic leukemia zinc finger protein. *The Mount Sinal J. Med.* 61:6, 538 (MM4), 1994.
180. Shaknovich R, English MA, Melnick A, Li J, Reddy J, Weiland S, Acs G, Waxman S, Licht J: Characterization of the PLZF protein and its fusion proteins with RAR-alpha generated in t(11;17) associated acute promyelocytic leukemia. *The Mount Sinal J. Med.* 61:6, 538 (MM5), 1994.
181. Chen A, Licht J, Wu Y, Hellinger N, Scher W, Waxman S: Retinoic acid (RA) is required for and potentiates differentiation of acute promyelocytic leukemia (APL) cells by nonretinoid agents. *The Mount Sinal J. Med.* 61:6, 539 (ND2), 1994.
182. Ferrari A, Adamski J, Waxman S: A novel therapeutic approach for the treatment of advanced prostate cancer based on differentiation induction. *The Mount Sinal J. Med.* 61:6, 540 (ND24), 1994.
183. Waxman S: Retinoids as chemopreventive agents in epithelial tumors. *Cancer Investigation*, Vol. 13, Supplement 1, 1995.
184. Jing Y-K Zhang J, Waxman S, Mira-y-Lopez R: Retinoids upregulate cytokeratins 8 and 18 in T47D human breast cancer cells. *Amer. Asso. Cancer Res.* 1995.



185. Mira-y-Lopez R, Jing Y, Waxman S: Retinoic acid receptor (RAR $\beta$ ); differential expression in mammary "Stem" cells, lactating cells and malignant breast cells. *Amer. Assoc. Cancer Res.* 1995.
186. Tang HY, Waxman S, Manfredi JJ: The tumor suppressor protein P53 acquires the ability both to bind DNA and to translocate to the nucleus in response to DNA damage. *Amer Assoc. Cancer Res.* 1995.
187. Tao W, Stone N, Esseesse I, Waxman S, Ossowski L, Ferrari A: Detection of circulating metastatic tumor cells in patients with advanced prostate cancer by PSA and PSM RT PCR. MSSM, Dept. of Medicine Annual Research Day, 1995.
188. Tang H-Y, Waxman S, Manfredi J: Cytoplasmic localization of p53 in breast carcinoma cell lines does not block p53-dependent G1 arrest in response to DNA damage. MSSM, Dept. of Medicine Annual Research Day, 1995.
189. Dong S, Zhu J, Guidez F, Zhong HJ, Xia ZO, Wang ZY, Zelent A, Licht J, Waxman S, Chomienne C, Chen Z, Chen SJ: POZ Domain mediated protein-protein interaction is responsible for the altered transactivation properties of PLZF-RAR $\alpha$  fusion in acute promyelocytic leukemia with t(11;17) translocation. *Blood* 86: Sup. 1, (#3013) 1995.
190. Zelent A, Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R: Expression of the APL translocation gene, PLZF, suggests a role for its product in early haemopoiesis. *Blood* 86: Sup. 1, (#565) 1995.
191. Waxman S, Manfredi J, Scher W, Scher B, Miller WHJr., Chen Z: A rational basis for the treatment of acute promyelocytic leukemia (APL) by combination differentiation and cytotoxic chemotherapy. *Blood* 86: Sup. 1, (#1052) 1995.
192. Li J-Y, Yeyati P, Zelent A, Chen Z, Chen S-J, Waxman S, Licht JD: DNA binding and transcription regulation by the promyelocytic leukemia zinc finger (PLZF) protein. *Blood* 86: Sup. 1, (#1034), 1995.
193. Shaknovich R, Weinberg RS, Zelent A, Reed A, Strutt P, Waxman S, Licht JD: The promyelocytic leukemia zinc finger protein has growth suppressive activity disrupted in t(11;17) associated APL. *Blood* 86: Sup. 1, (#1032), 1995.
194. Mao M, Yu M, Tong JH, Huang OH, Zhu J, Wang ZY, Waxman S, Lanotte M, Chen SJ, Chen Z: RIG-E, a human homologue of the murine LY-6 family, is induced by ATRA during acute promyelocytic leukemia cell differentiation. *Blood* 86: Sup. 1, (#3064), 1995.
195. Ferrari AC, Tao W, Esseesse I, Waxman S, Stone N: Clinical significance of circulating prostate cancer cells detected by PSA and PSM. *Cancer Invest.* 14: Suppl. 1, 51-52, 1996.
196. Huang Y, Waxman S: Differentiation therapy with novel inducers. *Cancer Invest.* 14: Suppl. 1, 58, 1996.
197. Tang HY, Hellinger N, Manfredi JJ, Waxman S: p21 induction is associated with differentiation in acute promyelocytic leukemia (APL) cells. *Proc. Amer. Assoc. Cancer Res* 37: 509-510 (#3483), 1996.
198. Huang Y, Waxman S: Phenyl butyrate (PB) enhances fluorodeoxyuridine (FUdr)/leucovorin (LV) growth inhibition of human colon carcinoma HT29 and induces differentiation and p21<sup>WAF1</sup> protein expression. *Proc. Amer. Assoc. Cancer Res* 37:203 (#1384), 1996.

199. Jing Y, Waxman S, Mira-y-Lopez R: Interactive regulation of urokinase plasminogen activator gene transcription by retinoic acid and cAMP in breast cancer cells. *Proc. Amer. Assoc. Cancer Res* 37: 502 (#3430), 1996.
200. Tao W, Ossowski L, Waxman S, Platica M, Ferrari A: Retinoids induce apoptosis of androgen dependent and independent prostate cancer cells and androgens potentiate this effect. *Proc. Amer. Assoc. Cancer Res* 37: 202 (#1383), 1996.
201. Ferrari AC, Tao W, Baldwin Y, Ossowski L, Waxman S, Stone N: Detection of circulating metastatic tumor cells by PSA may be useful to identify subgroups of advanced prostate cancer patients. *Proc. Amer. Assoc. Cancer Res* 37:247 (#1686), 1996.
202. Huang Y, Waxman S: Enhanced p21<sup>WAF1</sup> expression, differentiation, and growth inhibition of human colon carcinoma cell lines result from combined treatment with interferon gamma (IFN gamma) and phenylbutyrate (PB). *Proc. Amer. Assoc. Cancer Res* 38:87 (#582), 1997.
203. Zelent A, Zhu J, Lanotte M, Gallagher R, Waxman S, Heyworth CM, Enver T: Differential expression of retinoid receptors during multilineage differentiation of haemopoietic progenitor cells-role of the RAR alpha2 isoform in normal granulopoiesis and leukemia. *Blood* 90: 45a-46a (#186), 1997.
204. Yeyati PL, Shaknovich R, Waxman S, Zelent A, Licht JD: The RAR alpha-PLZF protein generated in t(11q23;17) - Associated acute promyelocytic leukemia displays oncogenic properties. *Blood* 90: 245a (#1076), 1997.
205. Ball HJ, Li J-Y, Zelent A, Waxman S, Licht JD: Binding of the promyelocytic leukemia zinc finger (PLZF) protein to a genomic binding site is modulated by the conserved POZ domain and phosphorylation. *Blood* 90: 321a (#1434), 1997.
206. Dai J, Hellinger N, Waxman S: Induction of apoptosis by the combined activity of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and ascorbic acid (AA) in t(14;18) B-cell lymphoma. *Blood* 90: 325a (#1449), 1997.
207. Dai J, Jin Y-K, Waxman S: Signal transduction by retinoic acid leads to the induction of two differently mediated proteolytic activities in NB4 cells. *Blood* 90: 325a (#1450), 1997.
208. Waxman S: Novel differentiation agents. *Cancer Detection and Prevention* 22: S-212 (#547), 1998.
209. Waxman S: Novel differentiation agents in clinical trial. *Cancer Investigation* 16: S (#16), 1998.
210. Liu TX, Zhang JW, Zhang RB, Wu JS, Tao J, Tong JH, Yu M, Sun YM, Lanotte M, Waxman S, Zhu L, Chen SJ, Chen Z, Mao M: Identification of the molecular pathways underlying the retinoic acid-induced differentiation of acute promyelocytic leukemia cells. *Blood* 92: S-193a (#784), 1998.
211. Zhu J, Guidez F, Owen GI, Chew YP, Waxman S, Mittnacht S, Zelent A: Acute promyelocytic leukemia Associated PLZF protein interacts with the retinoblastoma tumour suppressor gene product. *Blood* 92: S-213a (#868), 1998.
212. Cheng G-X, Meng X-Q, Jin X-L, Wang L, Zhu J, Xiong SM, Zhu X-H, Waxman S, Licht J, Zelent A, Dong S, Chen G-Q, Chen S-J: Establishment of transgenic leukemia mice models with acute promyelocytic leukemia-specific fusion genes PLZF-RARa and NPM-RARa. *Blood* 92: S-213a (#870), 1998.

213. Zhu J, Guo W-M, Yao Y-Y, Zhao W-L, Cai X, Ju B, Sun G-L, Wang H-L, Chen S-J, Waxman S, Chen Z, Caen J, Wang Z-Y: Different modulation of tissue factor on acute promyelocytic leukemia cells by ATRA, arsenic trioxide and daunorubicin. *Blood* 92: S-357a (#1470), 1998.
214. Zhang MM, Wu JS, Kan LX, Shen Y, Ye M, Zhou J, Cao WJ, Waxman S, Wang YX, Chen SJ, Chen Z: Full-length cDNA cloning based on the study of hematopoietic stem/progenitor CD34+ cell gene expression. *Blood* 92: S-370a (#1525), 1998.
215. Jing Y, Dai J, Cohen M, Weinberg RS, Chalmers-Redmen RME, Tatton WG, Waxman S: Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) induced selective apoptosis in acute promyelocytic leukemia (APL) cells involves a hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) dependent pathway. *Blood* 92: S-595a (#2453), 1998.
216. Chen G-Q, Zhu X-H, Shen Y-L, Jing Y-K, Cai X, Jia P-M, Chen S-J, Waxman S, Chen Z: Pharmacologic concentrations of arsenic trioxide induces growth inhibition and apoptosis in malignant lymphocytes and multiple myeloma cells. *Blood* 92: S-638a (#2632), 1998.
217. Niu C, Yan H, Sun HP, Liu JX, Gu BW, Su XY, Cao Q, Waxman S, Chen Z, Chen SJ, Shen ZX, Wang ZY: Treatment of de novo and relapsed acute promyelocytic leukemia patients with arsenic trioxide. *Blood* 92: S-678a (#2796), 1998.
218. Dai J, Jing Y, Hellinger N, Weinberg, R, Waxman S: Mechanism of arsenic trioxide induced growth inhibition and apoptosis in malignant cells. *Proc Amer Assoc Cancer Res* 39: 68 (#468), 1998.
219. Jing Y, Nakajo S, Nakaya K, Waxman S, Mira-y-Lopez R: Estrogen receptor regulates cellular retinoic acid binding protein II expression via its regulation of retinoic acid receptor alpha in T47D human breast cancer cells. *Proc Amer Assoc Cancer Res* 39: 275 (#1879), 1998.
220. Waxman S, Jing J: Arsenic trioxide-induced selective apoptosis as a treatment of cancer. *Cancer Investigation* 17: 52-53 (#44), 1999.
221. Zhang T, Ziong H, Kan LX, Zhang CK, Jiao XE, Fu G, Lu L, Tong JH, Gu BW, Yu M, Licht J, Waxman S, Zelent A, Chen E, Chen SJ: Genomic sequence, structural organization, molecular evolution and aberrant rearrangement of promyelocytic leukemia zinc finger gene. *Blood* 94: 56a (#236), 1999.
222. Waxman S, Zelent A, Melnick A, Licht JD, Monks A, Sausville E, Jing YK: Development of novel agents targeted to overcome site-specific transcriptional repression of leukemia. *Blood* 94: 61a (#262), 1999.
223. Jing Y, Wang R, Xia L, Chen GQ, Chen Z, Miller M, Waxman S: Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. *Blood* 94: 505a (#2260), 1999.
224. McConnell MJ, Ball HJ, Waxman S, Licht JD: The PLZF protein represses the IL3 receptor-alpha chain promoter by interference with c-myb. *Blood* 94: 692a (#3063), 1999.
225. Zhu J, Jiao XF, Sun YW, Tong JH, Guo WM, Wang B, Chu HY, Zhu XH, Zhang JW, Wang YX, Wang ZY, Waxman S, Chen SJ, Chen Z: Cloning of RIG-I, a novel NTP-utilizing enzyme up-regulated during ATRA-induced differentiation of acute promyelocytic leukemia cells. *Blood* 94: 145b (#3815), 1999.
226. Waxman S: Retinoids in cancer therapy – is there a role other than acute promyelocytic leukemia (APL). *Cancer Invest* 19: 44-45 (#38), 2000.

227. Jing Y, Xia LJ, Hellinger N, Waxman S: PML-RAR alpha degradation is necessary for the synergistic differentiation induced by all-trans retinoic acid (ATRA) in combination with butyrates or HMBA. *Proc. Amer. Assoc. Cancer Res.* 41: 807 (#5124), 2000.
228. Shen ZX, Shen Y, Li JM, Shen Y, Yan H, Waxman S, Chen SJ, Chen Z: Treatment of relapsed acute promyelocytic leukemia patients with low dose of As<sub>2</sub>O<sub>3</sub>. *Blood*, 96: 827a, (#3576), 2000.
229. Zhang JW, Zhu HQ, Niu C, Tiao J, Liu TX, Zhao CJ, Zhang QH, Yu Y, Jia PM, Wang HH, Mao M, Wang ZY, Tong JH, Waxman S, Chen SJ, Chen Z: Functional study on several novel retinoic acid induced genes (RIGs). *Blood*, 96: 136b, (#4281), 2000.
230. Jing Y, Xia L, Luo D, Waxman S: GST pi prevents As<sub>2</sub>O<sub>3</sub>-induced apoptosis but not growth inhibition in prostate cancer cells. *Proc. Amer. Assoc. Cancer Res.* 42: 447 (#2401), 2001.
231. Waxman S: Silenced retinoic acid response genes – future targets for therapy. *Cancer Invest* 20: 64-65 (#49), 2001.
232. Jing Y, Xia L, Waxman S: Removal of the dominant negative PML-RAR alpha protein and upregulation of C/EBPε expression are necessary for all trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. *Blood* 98: 306a (#1294), 2001.
233. Chen G-Q, Zhou L, Chen Z, Jing Y, Styblo M, Waxman S: Arsenic trioxide-induced apoptosis of acute promyelocytic leukemia (APL) cells is associated with reduced AKT phosphorylation and modified by arsenic methylation. *Blood* 98: 306a-307a (#1295), 2001.
234. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Waxman S, Anderson KC: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. *Blood* 98: 375a (#1578), 2001.
235. Petrie KR, Guidez F, Howell L, Healy L, Waxman S, Greaves KF, Zelent A: Role of a novel class II histone deacetylase in normal and leukemia-associated transcriptional repression. *Blood* 98: 568a (#2380), 2001.
236. Waxman S: Identification of new agents or combination therapies to induce differentiation and apoptosis in malignant cells. *Journal of Biological Regulators and Homeostatic Agents* 15: 411 (#31), 2001.
237. Bolterman SA, Reid JM, Covey JM, Alley M, Waxman S, Ames MM: Murine pharmacokinetics of the potent differentiating dithiophene dione analogs NSC 682994 and NSC 656240. *Proc. Amer. Assoc. Cancer Res.* 43: 78, (#393), 2002.
238. Xia L, Han R, Fang Q, Waxman S, Jing Y: Boswellic acid acetate induces apoptosis through caspase mediated pathways. *Proc. Amer. Assoc. Cancer Res.* 43: 80, (#400), 2002.
239. Jing Y, Xia L, Zhou L, Waxman S: Effect of arsenic trioxide with buthionine sulfoximine treatment of lymphoma is discordant in vitro and in vivo. *Proc. Amer. Assoc. Cancer Res.* 43: 586, (#2905), 2002.
240. Chen G-Q, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S: Methylated trivalent arsenicals are potent apoptotic inducers in acute promyelocytic leukemia and lymphoma cells. 2<sup>nd</sup> Conference on Molecular Mechanisms of Metal Toxicity and Carcinogenesis, 2002.

241. Xia L, Lu M, Waxman S, Jing Y: All-trans retinoic acid (ATRA) treatment of acute promyelocytic leukemia NB4 cells results in cleavage of PML-RAR alpha protein that is independent of proteasome and caspase pathways. *Blood* 100: 541a, (#2123), 2002.
242. Xu K, Chung D, Glasow A, Guidez F, Monks A, Stegmaier K, Golub TR, Zelent A, Waxman S: Specific dithiophene analogs potentiate ATRA induction of acute promyelocytic leukemia cell differentiation and gene expression in vivo. *Blood* 100: 541a, (#2125), 2002.
243. Heredia ZD, Mann KK, Schipper HM, Waxman S, Miller WH: Effect of methylation on the arsenic-mediated apoptosis in APL cells. *Blood* 100: 222b, (#4405), 2002.
244. Jing Y, Xia L, Waxman S: Heavy metals induce differentiation and apoptosis in acute promyelocytic leukemia cells by PML-RAR alpha degradation dependent and independent pathway. *Blood* 100: 226b, (#4422), 2002.
245. Lu M, Xia L, Wu GS, Waxman S, Jing Y: Upregulated expression of cathepsin D plays a negative role during all-trans retinoic acid-induced differentiation of acute myeloid leukemia cells. *Blood* 100: 227b, (#4427), 2002.
246. Furman RR, Sirulnik A, Kamalu OO, Brenner RB, Paciucci PA, Gabrilove JL, Waxman S: A phase II study of arsenic trioxide in the treatment of relapsed and refractory low-grade lymphomas. *Blood* 100: 304b, (#4758), 2002.
247. Xu K, Chung D, Glasow A, Jing Y, Guidez F, Stegmaier K, Golub TR, Zelent A, Waxman S. Dithiophenes potentiate differentiation of APL cells by lowering the threshold for ligand mediated co-repressor/co-activator exchange with RAR alpha and enhancing changes in ATRA regulated gene expression. *Blood* 102: 859a, (#3195), 2003.
248. Zhou L, Furman R, Waxman S. Glutathione S-transferase pi (GSTpi) mediates NF-kappa B activation and sensitivity to arsenic trioxide induced apoptosis in lymphoma and chronic lymphocytic leukemia (CLL) cells. *Blood* 102: 864a, (#3214), 2003.
249. Jing Y, Xia L, Han R, Waxman S. Boswellic acid acetate activates caspase-3 indirectly by upregulation of death receptors. *Blood* 102: 212b, (#4569), 2003.
250. Petrie K, Howell L, Matutes E, Waxman S, Piris MA, Esteller M, Zelent A. The histone deacetylase 9 gene is regulated by multiple promoters and expresses lymphoid-specific isoforms. *Blood* 104: 317a-318a, (#1120), 2004.
251. Glasow A, von Lindern M, Waxman S, Zelent A. Hypermethylation of retinoic acid receptor alpha 2 (RARalpha2) promoter in human AML cells correlates with poor RARalpha2 expression and response to differentiation inducers. *Blood* 104: 320a, (#1129), 2004.
252. Waxman S. Can we cure APL without cytotoxic chemotherapy? *Cancer Invest.* 23: 19, (#16), 2005.
253. Shackelford D, Kenific C, Waxman S, Ren R. Arsenic trioxide targets the MDS1 and EVI1- containing oncoproteins for degradation by proteasome dependent and independent mechanisms. *Blood* 106: 461a, (#1612), 2005.
254. Lemmer ER, Villanueva A, Yea S, Peix J, Schwartz M, Narla G, Waxman S, Friedman S, Llovet JM. Blockade of Hedgehog pathway signaling inhibits growth of human hepatocellular carcinoma cell lines. *Hedgehog abstract*, 2006.